Annual Report (ESEF) • Feb 8, 2022
Preview not available for this file type.
Download Source FileALK-Abelló A/S
Bøge Allé 6-8
DK-2970 Hørsholm
45 45 74 75 76
www.alk.net
63717916529900SGCREUZCZ7P0202021-01-012021-12-312020-01-012020-12-312492
Regnskabsklasse D
https://www.alk.net/sustainability
https://www.alk.net/sustainability
https://www.alk.net/sustainability
https://ir.alk.net/corporate-governance
63717916
Alk-Abello A/S
Bøge Alle 6-8
2970 Hørsholm
xWizard version 1.1.1089.1, by EasyX Aps. www.easyx.eu
https://www.alk.net/sustainability
3377123133771231529900SGCREUZCZ7P0202021-01-012021-12-31cmn:ConsolidatedMember529900SGCREUZCZ7P0202021-01-012021-12-31cmn:ConsolidatedMember0529900SGCREUZCZ7P0202021-01-012021-12-31cmn:ConsolidatedMember1529900SGCREUZCZ7P0202021-01-012021-12-31cmn:ConsolidatedMember2529900SGCREUZCZ7P0202021-01-012021-12-31cmn:ConsolidatedMember3529900SGCREUZCZ7P0202021-01-012021-12-31cmn:ConsolidatedMember0529900SGCREUZCZ7P0202021-01-012021-12-31cmn:ConsolidatedMember1529900SGCREUZCZ7P0202021-01-012021-12-31cmn:ConsolidatedMember2529900SGCREUZCZ7P0202021-01-012021-12-31cmn:ConsolidatedMember3529900SGCREUZCZ7P0202021-01-012021-12-31cmn:ConsolidatedMember4529900SGCREUZCZ7P0202021-01-012021-12-31cmn:ConsolidatedMember5529900SGCREUZCZ7P0202021-01-012021-12-31cmn:ConsolidatedMember6529900SGCREUZCZ7P0202021-01-012021-12-31cmn:ConsolidatedMember7529900SGCREUZCZ7P0202021-01-012021-12-31cmn:ConsolidatedMember8529900SGCREUZCZ7P0202021-01-012021-12-31529900SGCREUZCZ7P0202020-01-012020-12-31529900SGCREUZCZ7P0202020-12-31529900SGCREUZCZ7P0202019-12-31529900SGCREUZCZ7P0202021-12-31529900SGCREUZCZ7P0202020-12-31529900SGCREUZCZ7P0202020-12-31ifrs-full:IssuedCapitalMember529900SGCREUZCZ7P0202020-12-31ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember529900SGCREUZCZ7P0202020-12-31ifrs-full:RetainedEarningsMember529900SGCREUZCZ7P0202021-01-012021-12-31ifrs-full:RetainedEarningsMember529900SGCREUZCZ7P0202021-01-012021-12-31ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember529900SGCREUZCZ7P0202021-12-31ifrs-full:IssuedCapitalMember529900SGCREUZCZ7P0202021-12-31ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember529900SGCREUZCZ7P0202021-12-31ifrs-full:RetainedEarningsMember529900SGCREUZCZ7P0202019-12-31ifrs-full:IssuedCapitalMember529900SGCREUZCZ7P0202019-12-31ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember529900SGCREUZCZ7P0202019-12-31ifrs-full:RetainedEarningsMember529900SGCREUZCZ7P0202020-01-012020-12-31ifrs-full:RetainedEarningsMember529900SGCREUZCZ7P0202020-01-012020-12-31ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember529900SGCREUZCZ7P0202020-12-31ifrs-full:IssuedCapitalMember529900SGCREUZCZ7P0202020-12-31ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember529900SGCREUZCZ7P0202020-12-31ifrs-full:RetainedEarningsMember529900SGCREUZCZ7P0202021-12-31cmn:ConsolidatedMember529900SGCREUZCZ7P0202021-01-012021-12-31cmn:ConsolidatedMember0529900SGCREUZCZ7P0202021-01-012021-12-31cmn:ConsolidatedMember1iso4217:DKKiso4217:DKKxbrli:shares
Annual report 2021
Allergy solutions for life
ALK-Abelló A/S
Bøge Allé 6-8
DK-2970 Hørsholm
Denmark
CVR no. 63 71 79 16
Cover picture: ALK has begun developing an allergy immunotherapy tablet for potentially life-threatening peanut allergy.
Management’s review • Annual report 2021 • ALK 3
At the start of a complex manufacturing process, ALK turns peanut kernels into a powder to be used as a source material for the peanut tablets.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT offering. This is so we can build the allergy treatment market ahead of a planned introduction of ACARIZAX®, which, subject to approval, is targeted for 2025. Meanwhile, our new Jext® partnership with Grandpharma will further widen our footprint in China.
Carsten Hellmann, President & CEO
“ ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities.
In 2022, we expect continued progress with full-year revenue forecast to grow 8-12% organically, and increased operating profit (EBITDA). This is expected despite extraordinarily high R&D costs, and the support for new, short-term growth initiatives, such as ramping up in China and digital consumer activities, plus longer-term growth initiatives such as an entry into food allergy, developing a new adrenaline auto-injector, and the pursuit of paediatric indications for the tablets. COVID, unfortunately, will most likely remain a factor in the year ahead, and may cause short-term fluctuations in sales in some markets, but overall, we expect to continue to withstand this ongoing challenge.
We believe that these are realistic ambitions given the market potential, the business transformation we have delivered, and the unwavering commitment of everyone at ALK to deliver on the promises we have made. While we remain committed to delivering on our promises, we are also, as previously mentioned, investing to accelerate growth beyond 2025. That’s why we are already funding a number of high potential growth accelerators, which look many years beyond 2025.
The first of these is children. In Europe and North America, we are seeing significant growth in the number of children treated with our SLIT-tablets. To illustrate the importance of this, the vast majority of SLIT-tablet patients in the fast-growing market of Japan are currently under 18 years. That’s probably because parents, who may play down their own allergies and suffer in silence, are much more proactive when it comes to seeking treatment for their children.
Maintaining growth and improving profitability
Safeguarding and, potentially, accelerating growth
“ e pandemic proved manageable for ALK, not least due to the hard work “ of our employees.
Our ambition remains to deliver organic growth of 10% or more annually, and to ramp up profitability to an EBIT-margin of around 25% in 2025.
Management’s review • Annual report 2021 • ALK 5
depth and breadth in existing and new markets – via consumer engagement and new digital models, new channels, market share gains and additional registrations. At the same time, we will manage our legacy portfolio of SCIT and SLIT-drops products to further support overall growth.
Management’s review • Annual report 2021 • ALK 4
ALK is growing fast and is on course to deliver long-term, continuous growth with improving profitability, while also investing in, and executing, new projects and activities to deliver an EBIT in the range of 25% while safeguarding, and potentially accelerating growth, from 2025 onwards.
Throughout the year, COVID still impacted the lives of millions around the world, and ALK continued to prioritise the safety and well-being of its staff, as well as the supply of products for doctors and their patients. Despite some challenges – for example, schedules for certain clinical trials had to be revised – the pandemic proved manageable for ALK, not least due to the hard work of our employees and their flexibility in accommodating changes in working practices. Thanks in part to these efforts, our supply chain, inventories and distribution remained resilient to the raw materials and logistical challenges reported by multiple industries.
In 2021, ALK maintained its progress towards continuous growth and improved profitability as we successfully executed on our strategic priorities. Revenue grew by 12% on broad-based growth across all three sales regions, with tablets being the key driver of growth. Operating profit (EBITDA) increased by 35% in reported currency to DKK 534 million, driven by higher sales, margin improvements, and efficiencies.
Employee engagement and retention remain important areas of focus for us. Over the past year, ALK has implemented programmes to support engagement and retention, promote talent identification and development, and to develop our leaders. The 2021 employee engagement survey registered scores that were above the healthcare industry average and we are striving to further improve the attractiveness of working at ALK, using the valuable input from our employees, so we can continue to recruit and retain skilled employees.
In the process, we expect gross margins to gradually improve, while capacity costs relative to revenue will decrease from 2023, once we have completed large-scale clinical development work on the respiratory tablets. In addition, we continued to take steps on our sustainability journey, by ensuring that this priority becomes an integrated part of our overall business strategy.
The second opportunity is China, which is already one of the world’s largest markets for house dust mite allergy immunotherapy (AIT) and has the potential to become significantly larger. Right now, we are expanding our salesforce and strengthening market access activities with the aim of speeding up the adoption of our existing AIT# Management’s review
In 2023, we expect to complete our paediatric clinical trials in house dust mite and tree pollen allergic rhinitis, which should open the door to full paediatric coverage in Thirdly, we want to enter the market for adrenaline auto-injectors in the USA with an affordable, competitive, next-generation product. To achieve this, we have two development programmes – an external project with Windgap Medical and an in-house project, with the aim of submitting a regulatory filing to the FDA by 2024.
Continues Tablets, which already account for 45% of ALK’s total revenue, will still be the main growth engine, and we aim to continue their momentum by expanding prescriber
Dedicated to allergy solutions for life
In closing, we would like to thank ALK’s employees for their continuing efforts and their tireless commitment to providing allergy solutions for life. Their dedication and discipline are what allow us to deliver on the ambitious targets we have set, and to help as many allergy sufferers as possible. Special thanks are also due to our partners, without whom we could not succeed, and to the patients and prescribers who place their trust in us – a trust we never take for granted and work hard every day to maintain.
Finally, we want to develop a new, mainstream treatment for food allergy. In 2021, we completed a feasibility study confirming that ALK’s current tablet technology is suitable for this project, and we plan to start Phase I clinical development in 2022 with an initial project for peanut allergy. With very limited treatment options available for this potentially life-threatening allergic condition, we believe this move is an important step towards fulfilling our promise of becoming the allergy company.
Last, but not least, we would like to thank our shareholders. As ALK’s financial performance continues to improve towards our targets, we look forward to rewarding them through continued, long- term value creation. Each of these potential accelerators is being pursued at full speed and, if we can repeat our recent successes, they will help to establish a much larger and stronger ALK, capable of continuously generating attractive shareholder returns for many years to come.
Anders Hedegaard Chairman of the Board
Peanut drug substance samples are analysed in our state-of-the-art laboratories using high-performance liquid chromatography, whereby chromatograms show visualisations of the peanut drug substance alongside other allergens.
Carsten Hellmann President & CEO
ALK is a global allergy solutions company with a wide range of treatments, products and services to meet the unique needs of allergy sufferers, their families and doctors. Headquartered in Hørsholm, Denmark, the company is listed on Nasdaq Copenhagen (ALKB:DC/OMX: ALK B)
| Global presence | |||
|---|---|---|---|
| Established: 1923 | Employees: ~2,600 | Markets with ALK presence: 47 | Patients in treatment with ALK products*: ~2.1m |
| Revenue | |||
| North America: 17% | Europe: 72% | International markets: 11% | |
| Development in revenue (DKKbn) | |||
| 2017: 2.9 | 2018: 3.3 | 2019: 3.5 | 2020: 3.9 |
| SLIT-tablets (% growth in local currencies) | |||
| +29% | +42% | +45% | +8% |
| SCIT/SLIT-drops | Other | ||
| Production sites: 5 | |||
| ALK’s unique manufacturing processes ensure its products meet required quality standards and represent a significant barrier to potential competitors, making them an important factor in maintaining ALK’s market position | Number of most common respiratory allergies covered by ALK's tablets: >24,000 | Participated in clinical trials for the tablets: |
| Sustainability highlights 2021 | ||
|---|---|---|
| July ALK and Grandpharma team up to market the first adrenaline auto-injector in China | April Approval for paediatric use of the ragweed-tablet in the USA | November Diagnostics, allergy immunotherapy and/or adrenaline products made accessible to +100,000 additional patients |
| Q3: Revenue up 20% with tablet sales up 41% | ||
| December Data from ALK’s real-world evidence activities published in The Lancet Regional Health – Europe | February October ALK completes its three-year transformation and updates its strategy, including decision to enter food allergy Key approval in Europe for SCIT manufacturing | June Employee engagement score above industry benchmark based on 93% participation |
| CO2 emissions from production reduced by 42% compared to the 2019 baseline | November Formulation feasibility study optimisation effort completed for peanut allergy product | August December |
| Q2: Revenue up 13% with tablet sales up 23% | Full-year 2021: Revenue up 12%, tablet sales up 29%, EBITDA up 35% in reported currency | May First recyclable packaging solution for OSIRIS®, has a carbon footprint 19 times lower than before |
| Q1: Revenue up 9% with tablet sales up 32% | 50% of waste reused or recycled, up from 38% | Women made up 49% of all managers, up from 46% |
ALK expects growth across all sales regions in 2022, with revenue projected to increase by 8-12% organically in local currencies, and the tablet portfolio expected to remain the key growth driver.
(2021: 534), reflecting revenue growth and an improved gross margin, both attributable to tablet sales growth, as well as efficiencies. sales in Europe will increase in single digits whereas sales growth in North America is expected at around 10% and growth in International markets is expected to exceed 10%. However, in absolute terms, the majority of growth is expected to come from Europe.
| 2022 targets | |
|---|---|
| Revenue | 8-12% growth |
| Growth across all sales regions | The COVID pandemic continues to cause a degree of uncertainty regarding capacity at allergy clinics and patients’ behaviour, which may lead to some volatility in the quarterly results. |
| (2021: DKK 3,916 million) | Tablets, ALK’s single largest product category, will remain key to growth in 2022. ALK plans for strong tablet sales growth across its regions and estimates global tablet sales growth of around 20% in 2022, with double-digit growth across all three sales regions, led by market share |
| Continues | EBITDA DKK (Revenue growth rates are stated in local currencies, unless otherwise indicated) |
| Revenue | The growth, projected at 8-12% in local currencies, is expected to be broad-based across all sales regions. The mid-point of the projected revenue range assumes that |
| 625-725 million | Operating profit (EBITDA) is expected to increase to DKK 625-725 million |
| Operating profit (EBITDA) DKK | ~50 million increase in R&D costs (2021: DKK 534 million) |
This report contains forward-looking statements, including forecasts of future revenue, operating profit and cash flow, as well as expected business-related events. Such statements are, by their very nature, subject to risks and uncertainties, as various factors, some of which are beyond the control of ALK, may cause actual results and performance to differ materially from the forecasts made in this report. Without being exhaustive, such factors include, e.g., consequences of the global COVID pandemic, general economic and business-related conditions, including: legal issues, uncertainty relating to demand, pricing, reimbursement rules, partners’ plans and forecasts, fluctuations in exchange rates, competitive factors and reliance on suppliers. Additional factors include the risks associated with the sourcing and manufacturing of ALK’s products, as well as the potential for side effects from the use of ALK’s existing and future products, as allergy immunotherapy may be associated with allergic reactions of differing extents, durations and severities.
gains and market expansion, particularly in central and northern Europe, and Japan.
with the increased sales and efficiencies that come from utilising higher-volume production lines – are expected to lead to long-term margin improvements. In addition, ALK expects low single-digit sales growth from the remaining, non- tablet portfolio, mainly driven by SCIT products and the adrenaline auto-injector, Jext®.
As previously stated, capacity costs will be influenced by a planned increase in R&D expenses in order to complete the clinical development of the respiratory tablet portfolio, gather further evidence for the tablets’ use in children, secure tablet registrations in new geographies and progress the food AIT programme into clinical development. R&D costs for 2022 are estimated at around DKK 650-700 million, roughly a DKK 50 million increase over 2021. The increase mainly relates to activities that were originally scheduled for 2020-21 but were postponed due to the impact of COVID on patient recruitment for clinical trials.
The higher end of the projected revenue range assumes accelerated sales growth across all regions with tablets leading the way and faster market share gains, supported by continuing regulatory impetus towards evidence-based allergy immunotherapy (AIT) products in key markets. The lower end of the revenue range incorporates pricing pressures, particularly in selected markets in Europe, and/or more pronounced, negative effects from COVID.
Our industry-leading project teams meet regularly to brainstorm, share ideas, and discuss results – an essential part of the peanut tablet development project.
The gross margin is expected to improve by 1-2 percentage points on 61% in 2021, driven by efficiencies and higher sales – especially from tablets, with higher volumes absorbed by existing capacity. ALK will continue to allocate resources to the execution of its product and site strategy. These activities – in combination
Sales and marketing costs are expected to increase, although the ratio to revenue is expected to improve slightly versus 2021.# Management’s review • Annual report 2021 • ALK 11
The expected increase reflects investments in current and future growth drivers, including additional investments to expand in China, further consumer-to-Continues Management’s review • Annual report 2021 • ALK 11 patient initiatives and early preparations for future paediatric tablet launches. ALK will continue to seek to leverage its existing sales and marketing platforms to drive underlying margin improvement. projected at around DKK 400 million, with investments focused on supporting long-term growth ambitions relating to tablets and adrenaline auto-injectors, the further streamlining and specialisation of production facilities, as well as IT upgrades. Free cash flow is expected to be negative, mainly due to changes in working capital, including a one-off repayment of up to DKK 175 million in accrued rebates, originally anticipated as due for payment in 2021. On this basis, ALK expects the operating profit (EBITDA) to be in the range of DKK 625-725 million, exceeding the level of 2021 and in line with ALK’s long-term earnings ambitions of achieving a ~25% EBIT margin in 2025.
ALK has had a presence in China’s rapidly growing allergy treatment market for nearly 20 years. New allergy immunotherapy products must be documented and registered before they can be sold in China, and there are just three players in the market, including ALK, with a competitor’s SLIT-drops products the current leaders in a market worth around DKK 800 million annually.
In anticipation of this, ALK will ramp up its local presence over the next three years, increasing the size of its salesforce significantly, supporting education and training for allergy specialists, and recruiting back-office staff for essential disciplines such as management, medical and legal affairs, compliance, and sales and marketing.
Alongside this build-up, ALK has teamed up with local partner Grandpharma in an exclusive licensing agreement that will see ALK’s adrenaline auto-injector Jext® registered and launched in China. In addition, it is in the process of establishing a partner-based digitalisation strategy, to ensure an engagement platform for its future ambitions.
ALK enjoys a strong reputation locally for offering high-quality products which are prescribed via selected hospital-based clinics in key locations. The current range is focused on the SCIT product Alutard® for the treatment of house dust mite allergy, plus an associated diagnostic product, and these are building ALK’s reputation and market presence ahead of the introduction of ALK’s house dust mite tablet which, subject to approval, could be on the market from 2025 onwards.
Management’s review • Annual report 2021 • ALK 12
The peanut drug substance is carefully analysed via the electrophoretic SDS-PAGE method. The blue bands reveal proteins of different molecular weights.
Management’s review • Annual report 2021 • ALK 13
| DKK 2021 | DKK 2020 | DKK 2019 | DKK 2018 | DKK 2017 | EUR 2021 | EUR 2020 | |
|---|---|---|---|---|---|---|---|
| Amounts in DKKm/EURm | |||||||
| Income statement | |||||||
| Revenue | 3,916 | 3,491 | 3,274 | 2,915 | 2,910 | 527 | 469 |
| EBITDA | 534 | 395 | 241 | 136 | 253 | 72 | 53 |
| Operating profit (EBIT) | 292 | 150 | (49) | (14) | (96) | 39 | 20 |
| Net financial items | (13) | (49) | (17) | (42) | 39 | (2) | (7) |
| Profit before tax (EBT) | 279 | 101 | (31) | (50) | (7) | 38 | 14 |
| Net profit | 219 | 25 | (170) | (158) | 29 | 29 | 3 |
| Information on shares | |||||||
| Share capital | 11,141 | 11,141 | 11,141 | 11,141 | 11,141 | 11,141 | 11,141 |
| Shares in thousands of DKK 10 each | |||||||
| Share price, at year end | 336.1 | 312 | 283 | 285 | 295 | 461.2 | 42.0 |
| Net asset value per share | 38.0 | 31.9 | 25.0 | 16.3 | 9.6 | 5.7 | 4.2 |
| Key figures | |||||||
| Gross margin – % | 61.2 | 58.1 | 57.8 | 56.0 | 56.4 | 61.2 | 58.1 |
| EBITDA margin – % | 13.6 | 11.3 | 7.4 | 4.7 | 8.7 | 13.6 | 11.3 |
| Average number of employees (FTE) | 1,092 | 1,092 | 1,092 | 1,092 | 1,092 | 1,092 | 1,092 |
| Balance sheet | |||||||
| Total assets | 5,830 | 5,563 | 5,495 | 4,865 | 4,958 | 784 | 748 |
| Invested capital | 2,931 | 2,807 | 2,759 | 2,968 | 2,864 | 394 | 377 |
| Equity | 3,480 | 3,153 | 3,176 | 3,179 | 3,290 | 468 | 424 |
| Return on equity (ROE) – % | 6.6 | 0.8 | (1.6) | (5.3) | (5.1) | 6.6 | 0.8 |
| ROIC incl. goodwill – % | 10.2 | 5.5 | (0.5) | (3.3) | (3.1) | 10.2 | 5.5 |
| Pay-out ratio – % | - | - | - | - | - | - | - |
| Earnings per share (EPS) | 2.3 | 0.3 | (3.7) | (15.6) | (15.9) | 2.3 | 0.3 |
| Earnings per share (DEPS), diluted | 2.3 | (4.6) | (8.7) | (61) | (46) | 2.3 | (4.6) |
| Cash flow per share (CFPS) | 5.7 | 12.1 | 3.4 | 2.5 | 2.7 | 5.7 | 12.1 |
| Price earnings ratio (PE) | 172 | 1,092 | (356) | (61) | (46) | 172 | 1,092 |
| Share price/Net asset value | 11.0 | 8.8 | - | - | - | 11.0 | 8.8 |
| DKK 2021 | DKK 2020 | DKK 2019 | DKK 2018 | DKK 2017 | EUR 2021 | EUR 2020 | |
|---|---|---|---|---|---|---|---|
| Cash flow and investments | |||||||
| Depreciation, amortisation and impairment | 242 | 255 | 232 | 333 | 33 | 33 | 40 |
| Cash flow from operating activities | 468 | 132 | (157) | (387) | (387) | 63 | (27) |
| Cash flow from investing activities | (266) | (245) | (199) | (358) | (358) | (36) | (33) |
| – of which investment in intangible assets | (45) | (26) | (52) | (27) | (3) | (6) | (3) |
| – of which investment in tangible assets | 245 | 255 | 132 | 333 | 33 | 33 | 40 |
| – of which acquisitions of companies and operations | 301 | (245) | (157) | (387) | (387) | 40 | (33) |
| Free cash flow | (294) | (94) | (745) | (294) | (94) | (745) | (294) |
| Revenue growth – % | |||||||
| Organic growth | 12% | 8% | (1)% | (1)% | (6)% | 12% | 8% |
| Exchange rate differences | - | - | 1% | (1)% | - | - | - |
| Acquisitions/divestments | - | - | - | (218) | (196) | - | - |
| Total growth revenue | 12% | 8% | - | (218) | (196) | 12% | 8% |
Read the ESG key figures overview here
For definitions and reconciliation of alternative performance measures, see page 90
Management’s review • Annual report 2021 • ALK 14
ALK’s full-year revenue for 2021 increased 12% to DKK 3,916 million (3,491), in line with the improved outlook, issued on 11 November 2021, and reflecting strong performances in all sales regions.
| DKKm | 2021 | 2020 | Growth (l.c.) |
|---|---|---|---|
| Europe | 2,809 | 2,550 | 10% |
| North America | 683 | 573 | 23% |
| Int'l markets | 424 | 368 | 15% |
| Overall revenue | 3,916 | 3,491 | 12% |
(Comparative figures for 2020 are shown in brackets. Revenue growth rates are stated in local currencies, unless otherwise indicated)
| DKKm | 2021 | 2020 | Growth (l.c.) |
|---|---|---|---|
| SCIT/SLIT-drops | 1,655 | 1,673 | (1)% |
| SLIT-tablets | 1,774 | 1,370 | 29% |
| Other products | 487 | 448 | 10% |
| Overall revenue | 3,916 | 3,491 | 12% |
Sales growth was largely fuelled by tablets, revenue from which increased by 31% on market share gains and market expansion – predominantly on the take-up of ITULAZAX® and the halo effect this created for GRAZAX®. Furthermore, the convenience of tablets as a home-based treatment made them a useful option for patients unable to continue with their usual treatments due to COVID-related constraints. Sales of legacy allergy immunotherapy (AIT) products declined 4%, influenced by planned product discontinuations which reduced growth, the shift of patients to SLIT-tablets. Sales of other products increased 10% as lower Jext® sales were outweighed by a recovery in sales for the wider portfolio.
European revenue was up 10% at DKK 2,809 million (2,550), despite occasional constraints caused by resurgences of COVID. Overall revenue growth was driven by ALK’s tablet portfolio, sales of which grew 29% overall, continuing the strong positive trajectory of recent years. Sales of legacy products were largely unchanged as sales mostly recovered for SCIT products previously impacted by COVID, which had prevented or discouraged visits to allergy clinics. Meanwhile, sales of SLIT-drops declined on planned product discontinuations and 72% (73%) 42% (48%) 2021 (2020) 2021 (2020) 45% (39%) Management’s review • Annual report 2021 • ALK 15 5-year total revenue by geography 5-year total revenue by product line COVID-aside, market conditions were largely stable across Europe in 2021, and there were no notable changes affecting the pricing and reimbursement of AIT products, although the risk of pressure in selected markets remains.
Revenue from International markets increased 15% in local currencies to DKK 424 million (368). Growth was largely attributable to a strong performance from ALK’s largest market in the region – Japan – although there was sales growth in almost all International markets.
Revenue in North America recovered from the 2020 impact of COVID, growing by 23% in local currencies to DKK 683 million (573).
| Revenue by geography | Revenue by product line |
|---|---|
| Europe | SCIT/SLIT-drops |
| North America | SLIT-tablets |
| International markets | Other |
| 11% (11%) | 17% (16%) |
| 13% (13%) | |
| 72% (73%) | 42% (48%) |
| 2021 (2020) | 2021 (2020) |
| 45% (39%) |
DKKm
4,000
3,000
2,000
1,000
0
4,000
3,000
2,000
1,000
0
Europe
North America
SCIT/SLIT-drops
Other
SLIT-tablets
International markets# Management’s review
ALK’s full-year operating profit (EBITDA) increased 35% in reported currency to DKK 534 million (395), in line with the improved outlook, issued on 11 November 2021, and reflected higher sales and improved gross margin.
Cost of sales increased 5% in local currencies to DKK 1,520 million (1,463). The gross profit of DKK 2,396 million (2,028) yielded a gross margin of 61% (58%) which exceeded the orginal goal of a 1-2 percentage point improvement and mainly reflected increased sales – especially from tablets in Europe – although this was somewhat reduced by increased shipments to Torii in Japan, which yield lower gross margins.
ALK continues to see significant costs for compliance efforts to secure robustness in product supply, as well as the implementation of the product and site strategy.
| 2021E 5 Feb. outlook | 2021E 5 May outlook | 2021E 9 Aug. outlook | 2021E 11 Nov. outlook | 2021 Actual | |
|---|---|---|---|---|---|
| Revenue | +12% (l.c.) | +8-12% (l.c) | +9-12% (l.c.) | +10-12% (l.c.) | +11-12% (l.c.) |
| EBITDA | 325-425m | 375-425m | ~(200)m | 450-500m | ~(100)m |
| Free cash flow | ~(200-300)m | 500-550m | ~ +200m |
(Comparative figures for 2020 are shown in brackets)
| 2021 DKKm | % | 2020 DKKm | % | |
|---|---|---|---|---|
| Revenue | 3,916 | 3,491 | ||
| Gross margin | 61% | 58% | ||
| Revenue | ||||
| Revenue | ||||
| Gross profit | 2,396 | 2,028 | ||
| Cost of sales | 1,520 | 1,463 |
2021 revenue increased by 12% in local currencies to DKK 3,916 million (3,491). Exchange rate fluctuations did not materially impact reported revenue growth. Planned product discontinuations, which mostly involved SCIT/SLIT-drops products in Europe during Q1, impacted overall growth negatively by ~1 percentage point. The effect was negligible in the remaining nine months of the year.
Revenue growth
Gross margin
Capacity costs increased 13% in local currencies to DKK 2,105 million (1,877). R&D expenses increased by 23% in local currencies to DKK 631 million (515) in support of a planned increase in clinical trial activities. Sales and marketing expenses increased by 10% in local currencies, reflecting a gradual
Continues
| DKKm | % | DKKm | % | DKKm | % |
| :---- | :- | :---- | :- | :---- | :- |
| 4,000 | 20 | 4,000 | 80 | 800 | 20 |
| 3,250 | | 3,250 | 70 | 600 | 16 |
| 2,500 | | 2,500 | 60 | 400 | 12 |
| 1,750 | | 1,750 | 50 | 200 | 8 |
| 1,000 | 10 | 1,000 | 40 | 0 | 4 |
| 0 | 0 | 0 | 30 | | 0 |
| | | | 20 | | |
| | | | 10 | | |
| | | | 0 | | |
| 2017 | 2018 | 2019 | 2020 | 2021 | 2017 | 2018 | 2019 | 2020 | 2021 | 2017 | 2018 | 2019 | 2020 | 2021 |
normalisation of activity levels following the 2020 impact of COVID on business activities, but also operational leverage of ALK’s commercial activities. Administrative expenses increased 3% in local currencies. Net financials were a loss of DKK 13 million (loss of 49) mainly relating to interest payments and loan fees. Tax on the profit totalled DKK 60 million (76) and net profit was DKK 219 million (25).
mainly on upgrades to legacy production and the build-up of capacity for SLIT- tablets production.
to the settlement of incentive programmes and a refinancing of ALK’s loan and credit facilities. Currently, ALK has DKK 1.5 billion in credit facilities running until the end of 2024, of which, DKK 1.3 billion is currently unused.
Free cash flow was positive at DKK 202 million (56), which was better than originally expected due to higher earnings and the timing of repayment of accrued rebates. This result was in line with the improved outlook issued on 11 November 2021.
EBITDA (operating profit before depreciation and amortisation) increased 35% in reported currency to DKK 534 million (395) and was better than originally expected, driven by the higher sales and improving gross margin. Exchange rates had only a minor effect on operating profit.
Cash flow from operating activities improved to DKK 468 million (301) driven by higher earnings and receipt of a milestone payment related to the recently established Jext® partnership for China.
Equity totalled DKK 3,480 million (3,153) at the end of the year, and the equity ratio was 60% (57%). At the end of 2021, ALK held 148,528 of its own shares or 1.3% (1.9%) of the share capital.
Cash flow from investment activities was DKK minus 266 million (minus 245), Cash flow from financing activities was DKK minus 311 million (minus 62), relating
| 2021 DKKm | % | 2020 DKKm | % | |
|---|---|---|---|---|
| Research and development | 631 | 515 | ||
| Sales, marketing and administration | 2,105 | 1,877 | ||
| EBITDA | 534 | 395 |
| Research and development expenses | Percentage of revenue | Administrative expenses | Sales and marketing expenses | Percentage of revenue | EBITDA | EBITDA margin |
|---|---|---|---|---|---|---|
| 2021 DKKm % | 2021 DKKm % | 2021 DKKm % | 2021 DKKm % | |||
| 800 20 | 1,600 60 | 800 20 | 600 20 | |||
| 600 40 | 1,200 40 | 600 15 | 400 15 | |||
| 400 20 | 800 20 | 400 10 | 200 10 | |||
| 200 0 | 400 0 | 200 5 | 0 5 | |||
| 0 | 0 | 0 | ||||
| 2017 2018 2019 2020 2021 | 2017 2018 2019 2020 2021 | 2017 2018 2019 2020 2021 | 2017 2018 2019 2020 2021 |
(Comparative figures for 2020 are shown in brackets. Revenue growth rates are stated in local currencies, unless otherwise indicated)
influenced by 2 percentage points due to exchange rate fluctuations.
| Geography | Q4 2021 DKKm (l.c.) | Q4 Growth | Q4 2020 DKKm (l.c.) |
|---|---|---|---|
| Europe | 795 | 7% | 734 |
| North America | 193 | 20% | 155 |
| Int'l markets | 111 | 6% | 102 |
| Overall revenue | 1,099 | 9% | 991 |
| Product line | Q4 2021 DKKm (l.c.) | Q4 Growth | Q4 2020 DKKm (l.c.) |
|---|---|---|---|
| SCIT/SLIT-drops | 483 | 0% | 477 |
| SLIT-tablets | 509 | 23% | 409 |
| Other products | 107 | (2)% | 105 |
| Overall revenue | 1,099 | 9% | 991 |
Strong Q4 delivers results in line with latest outlook
ALK delivered 2021 full-year results in line with expectations following a Q4 which saw revenue growth of 9%. Growth was fuelled by continued strong tablet sales growth of 23%, during what is traditionally the peak season for allergy immunotherapy (AIT) treatment initiations. This compares with a Q4 2020 that saw extraordinarily high revenue growth of 16%, with tablet sales growth of 55% which was, in part, fuelled by a high number of shipments to ALK’s partner in Japan.
| 2021 (2020) | Q4 Highlights |
|---|---|
| Europe | 46% (41%) |
| North America | 10% (10%) |
| International markets | 18% (16%) |
| 2021 (2020) | Q4 Highlights |
|---|---|
| SCIT/SLIT-drops | 10% (11%) |
| SLIT-tablets | 72% (74%) |
| Other | 44% (48%) |
In Europe, revenue was up 7%, driven by strong uptake of the tablets. Tablet sales increased 31%, fuelled in particular
Continues
in central and northern Europe by the uptake of ITULAZAX® and the halo effect this had on GRAZAX®. Combined sales of SCIT and SLIT-drops were down 7%, reflecting COVID-related constraints in some countries and the ongoing transition of patients to tablets, while sales of other products declined 33% on low sales of the Jext® adrenaline auto-injector, influenced by fewer prescription renewals because of COVID and a Q4 2020 extension to its shelf life. Another factor was an industry- wide adjustment of rebates in the UK under the agreed rebate scheme, announced in December. Also in Q4, ALK downsized its commercial activities in Spain and Turkey to reflect the current market conditions for evidence-based AIT treatments.
to China. Revenue from Japan was, as planned, slightly below the high level of 2020, and impacted by fluctuations in the timing of shipments.
| Amounts in DKKm | Q4 2021 | Q4 2020 |
|---|---|---|
| Revenue | 1,099 | 991 |
| Cost of sales | 398 | 412 |
Gross margin improved to 64% (58%), reflecting higher sales – especially from tablets in Europe – but also the cost of compliance efforts to solidify robustness in product supply, as well as the implementation of the product and site strategy.# Management’s review
After forming a new, internal Sustainability Committee in 2021, ALK continued integrating sustainability into its overall business strategy. ALK remains a committed signatory of the UN Global Compact Principles and supports the UN Sustainable Development Goals. ALK also considers employee diversity and inclusion, responsible business practices, and environmental impact across the company’s value chain.
The driving force behind ALK’s sustainability efforts is ensuring ‘Access to Allergy Care for All’. This strategy includes expanding ALK products into new geographical markets directly or through partnerships, and into new segments such as children and adolescents. ALK ensures a comprehensive portfolio of quality allergy solutions through innovative research and development.
ALK’s sustainability strategy
ALK introduced tablet-based AIT to the ambition of securing registrations in new geographies and patient segments. In addition, ALK entered a partnership with Grandpharma, a Chinese pharmaceutical company, to expand the availability of its adrenaline auto-injector, Jext®, which is used for the emergency treatment of acute allergic reactions.
The availability of medicines is just one factor in broadening access to allergy care. A significant barrier to allergy treatment is the lack of access to specialist doctors. Therefore, ALK is partnering with healthcare systems to train healthcare professionals on how to diagnose and treat allergies. In 2021, this initiative resulted in approximately 3,800 healthcare professionals being educated.
Expanding ‘Access to Allergy Care for All’
ALK made allergy diagnosis, allergy immunotherapy (AIT) treatment, and adrenaline products available to more than 100,000 additional patients, bringing the total number of patients served to approximately 2.1 million. Furthermore, ALK’s digital channels mobilised more than 375,000 people to take action on their allergies and ALK tested several concepts in various countries to eliminate friction points on the path to prescriptions for the many untreated patients eligible for AIT treatment.
In 2021, ALK continued to take all necessary measures to protect employees from the various resurgences of COVID, while maintaining the pursuit of its strategic growth ambitions. This required a degree of flexibility to accommodate new ways of working. Nevertheless, ALK’s 2021 employee engagement survey confirmed that employees felt the company had prioritised their well-being and communicated effectively throughout this period. The survey had a participation rate of 93% and resulted in an overall engagement score of 8.2, which was 0.6 above the benchmark for the healthcare industry.
Diverse and engaged employees
A skilled, diverse and engaged workforce is essential to ALK’s success. ALK invests significantly to ensure all employees have equal opportunities to realise their full potential, regardless of age, gender, race, ethnicity, religion, disability, sexual orientation, or any other unique characteristic. In addition, ALK’s Cultural Beliefs: Do the right thing, Pursue growth, and Build bridges, are designed to inspire and empower employees to reach their full potential, in the pursuit of advancing allergy care for all.
At the end of 2021, ALK’s Board of Directors consisted of nine members. Of the six shareholder-elected members, two were women, meeting the target of 30%. Furthermore, women accounted for 67% of employee-elected Board members.
In 2021, the company took further steps towards increasing gender diversity among its senior leadership. At the end of the year, 29% of vice president and senior director positions were held by women, which was on track for ALK’s 2025 goal of at least 35%. The gender balance at manager and director levels remained on track for approximately 50%, with 53% women and 47% men. The number of women at vice president and senior director levels is expected to increase over the coming years, supported by ALK’s talent, mentoring and sponsorship programmes.
| Unit | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Environmental data | ||||
| Total CO2 emissions (Scope 1, Scope 2, refrigerants) | Tonnes | 11,258 | 11,263 | 9,644 |
| CO2 emissions (less renewables) | Tonnes | 7,130 | 12,213¹ | 4,676¹ |
| Energy consumption | MWh | 45,686 | 46,762¹ | 45,441 |
| Energy intensity | Ratio % | 30 | 33 | 31 |
| Renewable energy share | % | 45 | 20 | 38 |
| Water consumption | 127,520 | 122,461¹ | 110,530 | |
| Waste recycled from production sites | m³ | 50 | 38 | 38 |
| Unit | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Social data | ||||
| Workforce | Headcount | 2,593 | 2,486 | 2,406 |
| % female | % | 63 | 63 | 62 |
| % female | Times | 46 | 47 | 47 |
| Gender diversity (total) | 1.14 | 1.13 | 1.18 | |
| Gender diversity (all management levels) | 10 | 11 | 13 | |
| Gender pay ratio (men to women) | 0.32 | 2.9 | 3.1 | |
| Employee turnover ratio, | LTIF % | 3.1 | 3.5 | 2.7 |
| Lost time injury frequency | ||||
| Absence due to sickness |
| Unit | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Governance data | ||||
| Gender diversity (Board) | % | 33 | 34 | 34 |
| Board meeting attendance rate | % | 94 | 98 | 97 |
| CEO pay ratio | Times | 20 | 17 | 29 |
¹ Baseline for improvement target
² LTIF includes all work-related injuries resulting in an individual being physically or mentally unable to work. In 2021, injuries were only included if diagnosed by a competent medical professional.
Find out more Read the Financial highlights and key figures overview here Please see further information on the reporting practices for ESG key figures in ALK’s sustainability report, https://www.alk.net/sustainability
ALK’s journey towards reducing its environmental impact includes the optimisation of waste management, reduction of energy consumption, and elimination of CO2 emissions across the value chain. This will involve an increase in recycling, a transition to renewable energy sources, and a more circular life-cycle for ALK’s products and materials. In 2021, ALK improved waste management and recycling. The share of waste that was reused or recycled increased to 50%, up from 38% in 2020. In France, switching to biodegradable packaging materials and converting to 100% renewable energy at ALK’s production site in Varennes were just some of the initiatives taken to reduce ALK’s impact on climate.
Switching from plastic to recyclable cardboard packaging
ALK set a target to reduce its CO2 emissions by 60% in 2025, which includes emissions from Scope 1, Scope 2, transport, business travel, and company cars. In addition, ALK will work to secure valid and robust Scope 3 data as well as investigate potential material categories to include in its Scope 3 reporting by 2025. As a result of the company’s efforts, energy consumption remained at 2019 levels, despite a significant increase in production output, while CO2 emissions from manufacturing operations fell by 42% compared to the 2019 baseline of total emissions from non-renewable sources.
With an increase in awareness and concern from its patients and healthcare professionals, ALK developed a new packaging solution in 2021 for its OSIRIS® products in France. Stringent testing ensured the quality of the medicines would remain uncompromised with this new packaging solution. In addition to the sustainability benefits, the new packaging is also more user-friendly with its colour-coded design, which makes it easier to read, especially for patients who take multiple treatments. ALK intends to evaluate similar packaging solutions across the entire supply chain. The total carbon footprint of the OSIRIS® packaging is now 19 times lower than before, potentially reducing plastic consumption by up to 60 tonnes annually.
Policies and guidelines
ALK’s sustainability efforts are supported by a wide range of policies and guidelines designed to ensure everyday activities are aligned with the company’s long-term ambitions. Topics covered by specific policies include: sustainability as well as the environment, health and safety (EHS), diversity, remuneration, data ethics, tax, stakeholder communications, investor relations, anti-corruption and bribery, and whistleblowing. Additionally, ALK’s Code of Conduct details the company’s expectations on professionalism, honesty and integrity. In 2021, 97% of employees completed and signed off on the annual online training exercise covering the Code of Conduct.
Continues
Find out more in ALK’s sustainability report, https://www.alk.net/sustainability
Gross profit: 701 (579)
Gross margin: 64% (58%)
Research and development expenses: 179 (178)
Sales and marketing expenses: 372 (338)
Administrative expenses: 71 (72)
Operating profit/(loss) (EBIT): 79 (9)
Net financial items: (5) (5)
Profit/(loss) before tax (EBT): 74 (14)
Tax on profit: (2) 17
Net profit/(loss): 76 (31)
Capacity costs increased 5% to DKK 622 million (588), largely due to higher sales and marketing expenses, related to restructuring costs for changes to ALK’s setup in Spain and Turkey. R&D expenses were level with 2020.
Operating profit before depreciation and amortisation (EBITDA): 136 (64)
In North America, revenue increased 20%, driven by the ongoing recovery in sales across the portfolio after the very challenging market conditions resulting from COVID in 2020. Tablet sales in the region were up 40%, while sales of bulk allergen extracts (SCIT) increased 11%. Sales of other products and services increased 24%. EBITDA of DKK 136 million (64) was in line with the most recent outlook, reflecting higher sales, as well as improved gross margins. Growth was fuelled by continued strong tablet sales growth of 23%, during what is traditionally the peak season for AIT treatment initiations. Revenue from International markets grew by 6%, fuelled by product shipments
Continues# Management’s review
ALK’s precision extraction processes used to make the peanut allergy tablets is made possible by a Dia-Ultra Filtration machine.
ALK’s strategic focus areas
A year ago, ALK updated its strategy following the conclusion of a three-year strategic transformation programme designed to stimulate a new period of continued growth. All of this is underpinned by a company-wide ambition to lead the way on sustainability, through ALK’s ‘people and planet’ commitments. These strategic priorities map a path towards ALK’s financial ambitions for 2025 and beyond – and will shape an ALK capable of delivering continuous, high revenue and earnings growth, with annual revenue growth of 10% or more, and will improve the company’s EBIT margin towards around 25% in 2025. The priority for the immediate future is to build upon that successful transformation by targeting continuous growth and profitability, as ALK seeks to become ever more relevant to people with allergy.
The strategy is further supported by selected longer-term initiatives, which are designed to safeguard and potentially accelerate ALK’s longer-term growth trajectory towards 2030 and beyond. This will be achieved by extending the company’s leadership in respiratory allergy, expanding its position in anaphylaxis, establishing a presence in food allergy, and pursuing new innovations through research. The steps towards fulfilling these ambitions fall into four key focus areas: succeed in North America, complete and commercialise the tablet portfolio, consumer engagement and new horizons, and optimise for excellence.
Progress on the strategic priorities
ALK continued the execution of its strategy in 2021, making progress in each of the four focus areas despite the impact x Continues
Towards ‘25 in 25’ and growth beyond
In North America, ALK continued its efforts to mobilise allergy patients, accelerate tablet sales, and to secure paediatric and adolescent indications for ACARIZAX®/ODACTRA® and RAGWITEK®, as well as introducing other prescription allergy solutions. Overall, tablets sales in the region grew by 42% on increased uptake among key prescribers, improved sales margins in the USA, and reduced COVID-related restrictions, allowing Relentless focus on strategy execution in pursuit of ‘allergy care for all’ patients to visit clinics more freely once again. Growth was further supported by the strong early performance of ITULATEKTM in Canada. Even so, the long-established market barriers to the adoption of the tablets in the USA remained a challenge.
Work to increase traction in the USA for the tablet portfolio included the introduction and expansion of a telehealth partnership giving patients direct access to an allergy health professional, which saw patients mobilised to take action on their allergies, albeit still in small numbers.
| 2018-20 | Present | 2025 | 2025 and beyond | |
|---|---|---|---|---|
| • 37% average tablet sales growth | • ≥10% organic growth p.a. driven by tablets | • ≥10% organic growth p.a. | ||
| • Achieve an EBIT margin of around 25% in 2025 based on continued growth, improved gross margin and cost efficiencies | • Further expand respiratory allergy leadership, including paediatrics | |||
| • Cumulative earnings DKK 800m ahead of plan | • Improve efficiency, maintain quality, and build further tablet capacity | |||
| • Past issues cleaned up | • Further expand in China and other markets | • Roll out tablets for paediatric use | ||
| • Initiate clinical development of peanut AIT, 2024 US filing of next-generation adrenaline product, expand in China | • Expand in anaphylaxis | |||
| • Strong growth foundations | • Commercialise food AIT | • Late-stage clinical development of food AIT | ||
| • 60% reduction in CO2 emissions versus baseline | • Maintain focus on people and planet activities |
In 2022, ALK’s goal is to further grow its tablets business by increasing prescriber depth among key specialists and continuing to pursue partnerships in digital health. ALK also aims to drive growth in its legacy product sales and to obtain approval for the use of ACARIZAX®/ ODACTRA® in adolescents.
tablet – progressed as planned, and patient recruitment will continue in 2022, with both trials expected to complete in 2023. The trials represent some of the final steps towards full paediatric coverage for the tablets in Europe and North America, which will be an important driver of continued double-digit revenue growth for ALK.
Efforts to complete and commercialise the tablet portfolio advanced, with the aim of securing their use in new geographies and additional patient groups. In April, ALK received approval from the FDA for the use of RAGWITEK® in US paediatric patients, while December saw the filing of a US application covering the use of ODACTRA® in adolescents. Also in 2021, ACARIZAX® was approved for adult and adolescent use in the UK, and for adolescent use in an additional nine countries. There were also approvals for GRAZAX® in eight countries and RAGWIZAX® in two countries, the majority of which were in eastern Europe. There was also a first UK approval for ITULATEKTM for adults and in Russia for adults and adolescents.
COVID continued to impact ALK’s
paediatric trial in house dust mite-induced allergic asthma, in line with previous updates. The trial was initiated before the start of the pandemic as a regulatory commitment to the European Medicines Agency’s Paediatric Development Committee, to expand the current adult asthma indication in Europe by gathering equivalent paediatric data. During the pandemic, ALK has observed a significant reduction in the frequency of asthma exacerbations of almost 66% versus pre-pandemic levels among patient cohorts included in the trial. A reduction of asthma exacerbations has also been reported for society in general and is believed to be the result of virus containment measures, such as face masks and social distancing. Due to the low number of asthma exacerbations observed in the
trial, ALK now believes it is unlikely to fulfil its objective of demonstrating an effect on asthma exacerbations, and the company will begin a dialogue with authorities on possible next steps. Since house dust mite- induced allergic asthma is a comorbidity of allergic rhinitis, ALK nevertheless expects to gain full paediatric coverage via the abovementioned Phase III trials in allergic rhinitis. This development is not expected to impact ALK’s long-term financial SLIT-tablet portfolio covers five of the most common respiratory allergies ambitions and ALK remains committed to exploring the full potential of AIT in the treatment of allergic disease.
ALK’s REWEAL programme is designed to supplement the current clinical evidence base for allergy immunotherapy (AIT) by collating ‘real-world’ patient data from independent sources in multiple countries. In 2021, results from the ALK- sponsored REACT study were published by The Lancet Regional Health – Europe. effect on severe asthma exacerbations over the nine years. Finally, patients treated with AIT had fewer in-patient stays and shorter stays if admitted to hospital. REACT is just one example of how our understanding of the role of AIT in allergy and asthma has advanced significantly over recent years. In Europe, ALK’s ACARIZAX® is already approved for the treatment of both allergic rhinitis and allergic asthma, and the Global Initiative for Asthma, GINA, now recommends sublingual AIT as a treatment option in patients with house dust mite-induced allergic asthma. ALK will continue to invest in generating new data with the aim of building on these successes and expanding the knowledge base still further. REACT gathered data from more than 92,000 patients with both allergic rhinitis and asthma. It showed that AIT treatment was associated with long-term sustained reductions in the use of their existing medication for up to nine years after AIT treatment initiation. Patients with pre- existing asthma who were treated with AIT were also more likely to step down their asthma treatment regimens, while AIT was also associated with a preventative
ALK’s two paediatric Phase III trials in allergic rhinitis – in Europe and North America for the house dust mite tablet, and in Europe and Canada for the tree pollen
| Phase I | Phase II | Phase III | Filing | Marketed | |
|---|---|---|---|---|---|
| GRAZAX® | Adults and children – Allergic rhinitis (grass) | Adults and children – Allergic rhinitis (grass) | Adults and children – Allergic rhinitis (grass) 2007 | 2014 | |
| GRASTEK® | North America 2014/21 | ||||
| GRAZAX® | Europe & Int'l markets* 2017 | ||||
| RAGWITEK® | Adults and children – Allergic rhinitis (ragweed) | Adults and children – Allergic rhinitis (ragweed) | Adults and children – Allergic rhinitis (ragweed) 2020 | North America 2015/18 | |
| RAGWIZAX® | Adults – Allergic rhinitis and allergic asthma (HDM) | Europe & Int'l markets 2016/17 | |||
| ACARIZAX® | Adolescents – Allergic rhinitis (HDM) | Europe 2015/18 | |||
| ACARIZAX®/ODACTRA® | Adults – Allergic rhinitis (HDM) | North America 2017/18 |
Elsewhere, the Phase III registration trial in China of the house dust mite tablet in adult allergic rhinitis remains paused due to COVID, and ALK is in discussions with the relevant authorities on possible next steps.
For more information, ALK’s statutory annual report on sustainability, data ethics and gender diversity (as required by §99a, §99b, §99d and §107d of the Danish Financial Statements Act as well as Article 8 of the EU Taxonomy) is available at https://www.alk.net/sustainability# Management's review
MITICURE™ Japan*
Adults and children – Allergic rhinitis (HDM)
Adults - Allergic rhinitis and allergic asthma (HDM)
Adults – Allergic rhinitis (HDM)
ACARIZAX® International markets
ACARIZAX® China
ACARIZAX®/ODACTRA® Europe & North America
Children – Allergic asthma (HDM)
ACARIZAX®/ODACTRA® Europe & North America
In 2022, ALK’s goal is to further grow global tablet sales by approximately 20%, with double-digit growth across its three sales regions.
Children – Allergic rhinitis (HDM)
ODACTRA® North America
Adolescents – Allergic rhinitis (HDM)
Adults and children – Allergic rhinitis (Japanese cedar)
CEDARCURE™ Japan**
2018
ITULAZAX®/ITULATEK™ Europe & Canada
Adults – Allergic rhinitis (tree: birch family)
Children – Allergic rhinitis (tree: birch family)
2019/20
Progress on increasing consumer engagement continued, and Q2 saw the launch of ALK’s klarify digital engagement platform in Canada, bringing the total
Continues
ITULAZAX®/ITULATEK™ Europe & Canada
* Licensed to Abbott for south-east Asia and Seqirus for Australia/New Zealand
* Licensed to Torii for Japan
** Already marketed in selected markets
number of klarify countries to six. Metrics on the success of this platform remain encouraging and, during 2021, ALK mobilised more than 375,000 consumers worldwide via klarify, including more than 40,000 in the USA, versus targets of 250,000 and 20,000, respectively. ALK will continue this work in 2022 with a focus on converting mobilised consumers into allergy immunotherapy patients, so that this truly becomes an ‘end-to-end’ journey for people with allergy. Also in 2021, ALK signed an exclusive agreement with the China-based pharmaceutical company, Grandpharma, that will see its existing AAI, Jext®, become the first to be registered and launched in China. Work on the food allergy treatment initiative progressed well. In Q2, ALK concluded a development and licensing agreement with Catalent for the use of its ZydisTM fast-dissolving tablet technology – the same technology used in ALK’s existing respiratory tablet portfolio – for use in future food allergy products. This was followed, in Q4, by the successful completion of a formulation feasibility study confirming the suitability of ZydisTM for use in a peanut allergy product, and supporting ALK’s 2022 goal of initiating Phase I development in the first half of the year.
ALK’s ‘new horizons’ priority covers initiatives with the ability to accelerate the company’s long-term growth, including an expanded offering in anaphylaxis and an entry into food allergy treatment. On the first of these, ALK continued to advance two parallel adrenaline auto-injector (AAI) projects – one in-house, and one in partnership with Windgap – with the aim of a submission to the US FDA in 2024. In 2022, these programmes will progress further with the device development and chemistry, manufacturing and controls (CMC) work needed to produce initial batches for use in stability and reliability testing. These steps will generate
Food allergies can be life-threatening, and are often detected in early use of this technology in the food allergy programme, and in Q4 completed a feasibility study confirming its suitability for use in the clinical development of a peanut allergy product. This paves the way for the initiation of Phase I clinical development in the first half of 2022, which will draw upon ALK’s extensive knowledge and experience from the development of the respiratory tablets. It will also build upon evidence from earlier, clinical proof of concept work, by leading academic researchers, which has demonstrated that peanut sublingual AIT is efficacious, and may provide a safe and practical treatment for people living with peanut allergy.
childhood. They affect around 2.5% of people worldwide and are on the increase. In early 2021, ALK announced its intention to establish a presence in this area, initially covering allergy to peanut, which is one of the most common food allergies, and can last a lifetime. The priority ‘optimise for excellence’ covers ALK’s product and site strategy programme (PASS), amongst other initiatives. This aims to safeguard ALK’s core portfolio of legacy products by ensuring it remains viable in the long- term, which, in part, means upgrading
Continues
Since that initial announcement, progress has been both swift and encouraging. ALK’s approach is to adapt the fast- dissolving sublingual tablet technology already used in its respiratory tablet portfolio. In Q2, ALK finalised a development and licensing agreement with Catalent on the essential data for the planned regulatory submissions.
legacy production processes so that they continue to meet the very latest regulatory standards. A key element in this programme is the simplification of ALK’s production setup by reducing the number of different drug substances used for similar products. In October, this work took another important step towards completion when ALK received an EU regulatory approval opening the door to the necessary changes for its SCIT product line ALUTARD SQ®. In 2021, as part of this ongoing work, ALK submitted a total of 1,859 regulatory variations covering 129 products to 40 authorities around the world.
agility, employee engagement and retention, and its sustainability agenda. Through a series of organisational agility initiatives, ALK aims to ensure its future growth ambitions can be delivered by the necessary range and depth of engaged and motivated employees, each of whom benefits from a strong framework and culture of support when it comes to both talent and leadership development. ALK’s approach is rooted in its cultural values, which encourage open dialogue, honest feedback, and strong cross-organisational cooperation.
Market expansion is a key part of ALK’s growth strategy, especially in more mature allergy immunotherapy markets. The tablet portfolio is particularly important here because, in many cases, it brings growth that is additional to sales from the legacy portfolio. Further impetus can come from
In 2022, ALK’s goal is to maintain or improve upon the high engagement score achieved in the previous year. In addition, ALK will continue to take steps to prioritise sustainability within its business model with the aim of improving access to allergy care and addressing environmental impact across the value chain. A more in-depth summary of progress to date on the people and planet platform, as well as future goals, can be found in ALK’s sustainability report.
patients themselves, and ALK’s digital engagement strategy is designed to motivate new patients to take action on their allergies by connecting them with specialist doctors who can understand their needs, diagnose their condition and prescribe a relevant treatment that can improve their quality of life. In 2022, ALK’s goal is to further progress the PASS programme as well as ensuring there are no quality-related major interruptions to product supply. ALK’s experience, especially in the Nordic countries, has shown that existing prescribers of the tablets can become powerful advocates for their use, helping to expand the prescriber base among their peers and, in turn, driving increased prescription rates. In addition, the tablets are an attractive proposition to healthcare professionals in specialisms adjacent to allergy, such as paediatrics, ear, nose and throat, and to selected general practitioners.
Underpinning ALK’s efforts in each of the four focus areas is a business-wide commitment to people and planet, which addresses ALK’s future organisational
This model – of registering new products, building advocacy and market access, expanding the prescriber base, and mobilising patients – while predominantly applicable to Europe today, has shown increasing success each time ALK has launched a new tablet, from grass, to house dust mite, and most recently, to tree.
As a global allergy solutions company with a century of scientific knowledge and expertise, “ ALK’s business model is designed to help people to take control of their allergies and their lives.
| Deep understanding of natural allergens | Resources |
|---|---|
| Diverse talent | Raw materials, water and energy |
| Expertise from academic institutions | Efficient large-scale production of AIT |
| ~2,600 employees, a net addition of 100 employees | Financial resources |
| Standardising, formulating, developing and documenting AIT treatments in large-scale clinical programmes | 2.1 million |
| A profound understanding of allergy patients in treatment with ALK products | ALK share price up 364% since 31 December 2017 |
| >24,000 participants in clinical trials* for the tablets | Value created |
| * 22 Phase III trials |
High-performance liquid chromatography (HPLC) is just one of the pharmaceutical-grade analytical processes used to monitor the quality and consistency of ALK’s peanut product.
Corporate governance structure, including the Board of Board composition
ALK’s statutory corporate governance statement for 2021, pursuant to section 107b of the Danish Financial Statements Act, is available at https://ir.alk.net/ financial-reporting/risk-management Directors’ composition, competencies, activities, self-assessment process, and remuneration. The statement also describes key elements of ALK’s internal control and risk management systems related to financial reporting processes.# Management's review
At the Annual General Meeting (AGM) in 2021, Anders Hedegaard (Chairman), Lene Skole (Vice Chairman), Lars Holmqvist, Jakob Riis, and Vincent Warnery were all re-elected to the Board of Directors. Furthermore, Gitte Aabo, CEO of GN Hearing, and Bertil Lindmark, Chief Medical Officer of Galecto, were elected as new, independent members of the Board.
Based on its long-term strategy, ALK has identified the core competencies which must be represented in the Board of Directors for the Board to be able to support the strategy. To assess whether all core competencies are adequately represented, each shareholder-elected member of the Board has been asked to identify a maximum of four primary competencies they bring to the Board, considering ALK’s long-term strategy. They may also have knowledge or experience in areas other than the four primary competencies. The matrix shows the responses to the self-assessment process. Employee-elected members are not part of the competency self-assessment. For the Chairman and Vice Chairman, two additional competencies, specific to these roles, have been identified.
At the next AGM on 16 March 2022, the Board of Directors will propose the election as a new Board member of Alan Main, previously head of Consumer Healthcare and Executive Committee member at Sanofi. His nomination follows the decision of Vincent Warnery to step down in August 2021 after his appointment as CEO of Beiersdorf.
If the nomination of Alan Main is approved at the AGM, four out of seven shareholder-elected members will again be independent, according to the definitions set by the Danish Committee on Corporate Governance. This reflects the Board’s efforts to provide an adequate balance between independent and non-independent members.
No other changes to the Board of Directors will be proposed at the next AGM, as the Board’s annual self-evaluation process validated the skills and competencies of the current Board. As such, the Board is considered to have the right competencies to support ALK’s long-term value creation and strategic progress.
| Role competencies: | Core competencies | Executive Board | Experience in a global company | Life science industry | Consumer healthcare / OTC / Risk | Financial | Research experience | Experience from other companies | Commer- cial | Digitalisa- tion | with & Devel- opment | US market |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chairman & Vice Chairman | ||||||||||||
| Anders Hedegaard | Chairman | |||||||||||
| Lene Skole | Vice Chairman | |||||||||||
| Gitte Aabo | Member | |||||||||||
| Lars Holmqvist | Member | |||||||||||
| Bertil Lindmark | Member | |||||||||||
| Jakob Riis | Member | |||||||||||
| Vincent Warnery | Member** | |||||||||||
| Katja Barnkob | *** | |||||||||||
| Nanna Rassov Carlson | *** | |||||||||||
| Johan Smedsrud | *** |
The Danish Committee on Corporate Governance has set out a series of recommendations on corporate governance which has been adopted by Nasdaq Copenhagen. ALK’s Board of Directors actively applies these recommendations as inspiration for setting up structures, tasks and procedures, and ALK accounts for its compliance with the recommendations in an annual ‘comply- or-explain’ review. The most recent update to the Danish Committee on Corporate Governance’s recommendations took place in 2020 and came into effect from 2021. To ensure its continued compliance, ALK has made the following amendments to procedures and policies:
The review of all updated 40 guidelines is available at https://ir.alk.net/corporate-governance.
All shareholder-elected Board members are elected for a term of one year. In addition, the Board includes three employee-elected members, all elected for a term of four years. All Board members are presented on pages 42-43 of this annual report, with details of their specific directorships, and other relevant background information. The Board of Management is presented on page 44. There were no changes to the Board of Management in 2021.
| Find out more ALK’s statutory corporate governance statement: https://ir.alk.net/corporate-governance | Nationality | Gender diversity | Independence |
|---|---|---|---|
| Danish | Other | Male | 33% |
The Board of Directors’ ‘comply or explain’ review: https://ir.alk.net/corporate-governance
The remuneration policy was approved by the AGM in March 2021. Remuneration for the Board of Directors and the Board of Management is determined in accordance with ALK’s remuneration policy as adopted by the AGM. The policy is prepared in accordance with sections 139 and 139a of the Danish Companies Act as well as items 4.1.1-4.1.6 of the latest Danish Corporate Governance Recommendations.
The report provides an overview of the components in the remuneration for the Board of Directors and Board of Management, including an overview of the actual remuneration in 2021, its development during the past three years, as well as the shareholdings of Board of Directors and Board of Management members. The policy outlines the overall framework for remuneration. The objectives of the policy are to:
All remuneration for the Board of Directors and Board of Management followed the principles and framework outlined in ALK’s remuneration policy. Members of the Board of Directors each received a fixed annual fee for serving on the Board, with the Vice Chairman and Chairman receiving double and triple the annual fee, respectively. In addition, members received an additional fee for serving on the Board’s committees. The Board and committee fees remained unchanged from 2020 to 2021. For members serving on the Scientific Committee, a fee was set as outlined in ALK’s remuneration policy. Members of the Board are not offered share options, performance shares or other incentives as payment for their work on the Board or committees.
The remuneration of the Board of Management reflects a good year with strong financial results and solid progress on ALK’s strategic agenda. Both the short-term and long-term incentive plans were settled above target, while the base salary for members of the Board of Management was increased by 1.75%, in line with the general increase for ALK employees in Denmark – except for the CFO, who received an increase above the general level to bring his base salary closer to the market level.
Find out more The remuneration policy is available at https://ir.alk.net/corporate-governance.
| DKKt | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Board of Directors | |||||
| Base fees | 3,650 | 3,359 | 3,245 | 3,080 | 3,300 |
| Committee fees | 998 | 885 | 850 | 850 | 850 |
| Total | 4,648 | 4,244 | 4,095 | 3,930 | 4,150 |
| Board of Management | |||||
| Base salary | 17,276 | 16,804 | 15,104 | 14,229 | 16,775 |
| Short-term incentives (cash bonus) | 11,924 | 9,906 | 8,535 | 7,342 | 7,835 |
| Long-term incentives (grant value) | 6,371 | 6,204 | 6,863 | 12,376 | 13,228 |
| Sign-on bonus (cash) | - | - | - | 686 | 1,500 |
| Pension incl. social security | 1,396 | 1,345 | 1,298 | 1,151 | 1,584 |
| Other benefits | 703 | 741 | 803 | 814 | 932 |
| Termination benefits | 2,332 | ||||
| Total | 37,670 | 35,000 | 32,603 | 36,598 | 44,186 |
The remuneration report for 2021 will be presented for an advisory vote at the AGM on 16 March 2022.
| Share capital | DKK 111,411,960 |
| Nominal value | 10 DKK per share |
| No of A shares |
On 31 December 2021, ALK had 20,434 registered shareholders versus 17,697 at the end of 2020. The registered shareholders owned 98% of the share capital (98%).
Foundation, while all B shares are listed on Nasdaq Copenhagen and freely negotiable. Of the largest registered shareholders, the vast majority were institutional investors, particularly from Europe and North America. The international registered ownership was estimated at approximately 31% (23%), representing 52% of the free float of the B share capital, excluding the Lundbeck Foundation’s holding and treasury shares.# Management’s review
The remuneration report is available at https://ir.alk.net/corporate-governance.
At year-end, the closing price of ALK B shares on Nasdaq Copenhagen was DKK 3,430, up 37% since 31 December 2020. During the same period, the Danish OMXC25 increased by 17% and the Nasdaq Biotechnology Index decreased by 1%.
Return to shareholders yielded an average, annual return of 47% to shareholders.
The total market value of ALK’s B shares, excluding treasury shares, was DKK 34 billion at year-end versus DKK 25 billion at the end of 2020. Since end of 2017, shortly after the announcement of ALK’s new strategy, share price increases have yielded an average, annual return of 47% to shareholders.
ALK’s share capital is divided into A shares, AA shares and B shares. The A and AA shares are not listed and are predominantly held by the Lundbeck Foundation.
| No of AA shares | No of B shares |
|---|---|
| 920,760 units with 10 votes per share | 10,128,360 units with 1 vote per share |
| 92,760 units with 10 votes per share |
Two shareholders have reported to ALK that they held 5% or more of the shares on 31 December 2021:
To meet obligations to deliver shares under management incentive programmes, ALK held 148,528 of its own shares, or 1.3% of the share capital, versus 1.9% at the end of 2020. The holding was reduced during the year following the settlement of share option and performance share programmes. The current holding is considered sufficient to cover current obligations under long-term incentive programmes.
The Board of Directors considers that ALK’s financial resources, including credit facilities, continue to form a sufficient basis for executing ALK’s strategy and to fund investments. At the end of 2021, net interest-bearing debt amounted to DKK 516 million and leverage stood at 1.0 EBITDA (1.6).
The Board of Directors revisits the dividend policy and ALK’s capital structure on an ongoing basis. Accordingly, the Board of Directors will propose to the AGM, that no dividends are declared for 2021. This is based on a recommendation that dividend payments be suspended until ALK’s profitability further improves.
The Board of Directors and Board of Management held a total of 12,963 shares at year-end, corresponding to 0.1% of the share capital (0.1%).
Up to and including 11 March 2023, the Board of Directors is authorised to increase the share capital by up to DKK 11,141,196 (AA shares with a nominal value of up to DKK 1,012,836, and B shares with a nominal value of up to DKK 10,128,360). Capital increases may either be at a price below market price with pre-emption rights for existing shareholders, or at market price without pre-emption rights for B shareholders.
The Board of Directors is authorised for the period until 12 March 2024 to let the company acquire own B shares on a regular basis for a nominal value of up to DKK 11,141,196 (equivalent to 10% of the share capital). Such shares may only be acquired for an amount that, together with the treasury shares already held by the company, at no time exceeds a nominal value of 10% of the share capital. The consideration for such shares may not deviate by more than 10% from the official quoted price of the B shares on Nasdaq Copenhagen on the date of acquisition.
The daily trading liquidity during 2021 was largely unchanged and averaged DKK 30 million (31) per day in value.
In support of ALK’s growth strategy, the Board of Directors is extending its recommendation that dividend payments be suspended until ALK’s profitability further improves. Accordingly, the Board of Directors will propose to the AGM, that no dividends are declared for 2021. The Board of Directors revisits the dividend policy and ALK’s capital structure on an ongoing basis.
It is ALK’s objective to have a diversified shareholder base in terms of geography, investment profile and time horizon that shares the company’s vision and supports its long-term strategy. Accordingly, ALK’s investor relations (IR) activities aim to support the perception of ALK as an accessible, trustworthy, and professional company that provides relevant, accurate, balanced, and timely information to capital markets in order to enable both a fair valuation and regular trading of its shares.
According to ALK’s IR policy, the IR department is committed to:
During 2021, besides hosting regular telephone conferences, ALK representatives participated in many individual meetings and briefing calls with analysts and investors. ALK also presented at investor conferences and seminars targeting various audiences. As in-person meetings continued to be limited due to COVID, the engagement with investors and analysts was predominantly virtual.
A total of 26 announcements were published in 2021 (2020: 17), including investor news and reports on transactions by managerial staff. All announcements are available on ALK’s main corporate website, together with reports, presentations, recordings of telephone conferences, share price information, analysts’ estimates, and related information. Registered shareholders are encouraged to sign up at the InvestorPortal.
| Shareholder | Registered office | No of shares | Interest | Votes | Blomberg code | Reuters code | ADR ticker symbol | LEI code |
|---|---|---|---|---|---|---|---|---|
| Lundbeck Foundation | Copenhagen, Denmark | 920,720 A shares | 40.3% | 67.2% | ALKB_CO | AKABY | - | 529900SGCREUZ7P02 |
| 92,072 AA shares | ||||||||
| 3,474,827 B shares | ||||||||
| ATP | Hillerød, Denmark | 642,314 B shares | 5.8% | 1.3% | - | - | - | - |
| ALK (treasury shares) | Hørsholm, Denmark | 148,528 B shares | 1.3% | 3.2% | - | - | - | - |
| Stock exchange | Ticker symbol | Indices | ISIN |
|---|---|---|---|
| Nasdaq Copenhagen | ALK B | X4500 (healthcare), OMXCLCPI (LargeCap) and OMXCPI (all) | DK0060027142 |
The Lundbeck Foundation
A + AA shares (The Lundbeck Foundation): 1,012,792
A + AA shares (Other): 0
A + AA shares total: 1,012,836
B-shares (The Lundbeck Foundation): 3,474,827
B-shares (ATP): 642,314
B-shares (Other): 5,862,691
B-shares total: 10,128,360
The Lundbeck Foundation, one of Denmark’s largest commercial foundations, is the controlling shareholder of ALK, owning 67% of the votes and 40% of the capital. The Foundation grants a minimum of DKK 500 million each year to public biomedical and health science research with a particular focus on neuroscience. Its business activities encompass majority shareholdings in two other healthcare companies, H. Lundbeck and Falck, an international portfolio of life science venture companies, a portfolio of biotech start-ups based on research from primarily Danish universities, as well as management of securities of around DKK 24 billion.
Ownership structure
Find out more: Visit Investor Relations at https://ir.alk.net/investors
Contact Investor Relations
Per Plotnikof, Head of IR
Tel. +45 4574 7527
ALK’s Board of Management is responsible for the ongoing management of risks throughout the value chain, including risk mapping, the assessment of probabilities and potential consequences, and the relevant to ALK’s risk profile. It meets twice a year or more, as required, to perform its tasks. Risks are systematically assessed according to a two-dimensional matrix, rating the impact and probability of each risk. A risk management report with key enterprise risks and recommended mitigation plans is presented to Board of Management before it is submitted to the Board of Directors on an annual basis for their review and approval.
Description
The degree of market acceptance for a new product or drug candidate depends on several factors, including the demonstration of clinical efficacy and safety, cost-effectiveness, convenience and ease of administration, potential advantages over alternative treatment methods, competition, and marketing and distribution support. If ALK’s new products, primarily tablets, fail to achieve market acceptance, this could have a significant influence on the company’s ability to generate revenue. Even if market acceptance of the tablets is successfully achieved, the extent of their acceptance could influence the company’s ability to fully deliver on its sales-growth targets for these products. While acceptance of tablets continues to increase in most markets, market acceptance remains a risk for ALK primarily in the USA.
Price pressures mandated by authorities can have a significant impact on the company’s earnings capacity. In most of the countries in which ALK operates, prescription drugs are subject to reimbursement from, and price controls by, national authorities and healthcare providers. This often results in significant price differences between individual markets.# Management’s review
Exceptionally, governments and national authorities may introduce economic measures that also affect the pricing and reimbursement of medicines, for example, because of the impact of COVID on healthcare budgets or because of a major economic downturn. introduction of risk-reducing measures. Risk mitigation
The following is a description of ALK’s key enterprise risks, and the main initiatives taken to mitigate these risks. The risk movements compared to the previous year are indicated. ALK closely monitors economic, market and regulatory developments as they relate to product pricing, along with the competitive situation and initiatives in all important markets, with the aim of appropriate risk mitigation. The Board of Management has established a risk committee to assist it in meeting its overall responsibility for risk management. The Risk Committee comprises ALK regularly conducts extensive surveys of market conditions and similar factors and commits significant resources to providing information on its products to doctors and patients. Sales growth targets are set with a full understanding of the potential risks involved in successfully marketing any product and these are anticipated and managed so far as is possible. ALK continues its focus on market access strategy, especially in the USA, to make tablets a more attractive alternative for patients. representatives from each functional area ALK is strongly committed to evidenced-based medicine, based on strong clinical and health economic evidence as the basis for pricing and reimbursement. ALK actively engages in dialogue with authorities with the aim of securing fair pricing and reimbursement agreements and maintains a strong focus on its market access strategy.
Description: ALK’s products are subject to many statutory and regulatory requirements with respect to issues such as safety, efficacy, and production. The products may, in unexpected situations, be associated with allergic reactions of varying extents, durations and severities. Meeting high product quality standards is a prerequisite for the company’s ability to supply products and hence its competitive strength, and for the company’s earnings and sales. ALK has concentrated its key in-house production capacity at plants in Denmark, France, Spain and the USA. Although the plants are in areas that have not historically been hit by natural disasters, this geographical spread calls for risk planning to avoid emergencies, such as lack of, or poor access to, raw materials: for instance, pollen. Patents and other intellectual property rights are important for developing and retaining ALK’s competitive strength. As ALK works to rationalise its product portfolio, there may be risks associated with the discontinuation of its products. Among others, these may include potential disruption at manufacturing sites during decommissioning work, the loss of sales from products for which no suitable ALK substitute product exists, or the inability to meet sudden spikes in demand for other products due to patients switching from discontinued products. Dependency on third parties for supplying input for key production processes and commercialising the company’s products in several markets entails risks that ALK would not be subject to if the company possessed the necessary in-house capabilities.
Risk mitigation: ALK stringently monitors product quality and safety, both in clinical development and in sales and marketing activities. If, despite the high levels of quality and safety, a situation should occur in which it is necessary to recall a product, ALK has procedures in place to ensure that this can be managed swiftly and effectively and in accordance with regulatory requirements. Production and manufacturing processes are subject to periodic and routine inspections by regulatory authorities as a regular part of their monitoring processes to ensure that ALK observes the prescribed requirements and standards. ALK’s production processes and quality standards have been developed and optimised over many years. ALK has invested significantly to increase the robustness and compliance of the legacy business by reducing manufacturing complexity, and all possible steps are taken during portfolio rationalisation work to mitigate any potential impact on other areas of manufacturing or the wider business. ALK conducts risk planning including for the prevention of unwanted events, and preventative inventory management. ALK manages third party dependency risks through contractual stipulations, planning, monitoring, and joint steering committees.
Description: The future success of ALK depends on the company’s ability to maintain current products and to successfully identify, develop and market new, innovative drugs, which involves significant risks. A pharmaceutical drug must be subjected to extensive and lengthy clinical trials to document qualities such as safety and efficacy before it can be approved for marketing. During the development process, the outcomes of these trials are subject to significant risks. Even though substantial resources are invested in the development process, the trials may produce negative results.
Risk mitigation: ALK and its collaborative partners perform thorough risk assessments of their research and development programmes throughout the development and registration processes with the objective of risk mitigation to optimise the likelihood of the products reaching the market. ALK’s Scientific Committee is responsible for other patient-/product-related innovation activities. The committee advises on matters relating to R&D activities and other patient-/product-related innovation activities, including reviewing R&D programmes and the overall R&D pipeline. Failures or delays in the development process or in obtaining regulatory approvals may have a major impact for the patients not able to benefit from the products, and on the ability of ALK to achieve its long-term goals.
Description: Non-compliance with applicable regulations, legislation, or ALK’s Code of Conduct could negatively impact the company’s good reputation which is essential for operating within the pharmaceutical industry.
Risk mitigation: ALK strives to act professionally, honestly, and with high integrity throughout the company in relation to stakeholders. ALK’s Code of Conduct defines ALK’s high standard of ethical behaviour in relation to customers, employees, shareholders, society, suppliers, and partners. Immediate action is taken on substantiated non-compliance. Annually, all employees are asked to sign and confirm their knowledge of the Code of Conduct and to take an online test. Internal controls and policies are in place to safeguard ALK’s intellectual property rights. The risk that ALK might infringe patents or trademark rights held by other companies, as well as the risk that other companies may attempt to infringe the patents and/or trademark rights of ALK are monitored and, if necessary, suitable measures are taken.
Description: The threat of cyberattacks continues to grow significantly for ALK, as it does for most major companies. Disruption to IT systems, such as severe breaches of data security, may occur across the global value chain, where well-functioning IT systems and infrastructure are critical for the company’s ability to operate effectively.
Risk mitigation: ALK continuously manages this risk, among other ways, by having a security strategy in place to prevent intruders from causing damage to systems or gaining access to critical data and systems. Awareness campaigns, access controls, intrusion detection and prevention systems have all been implemented, further initiatives are planned, and systems are regularly upgraded to increase network security.
| Anders Hedegaard | Lene Skole1 (1959, Danish) | Gitte Aabo (1967, Danish) | Lars Holmqvist1 (1959, Swedish) | |
|---|---|---|---|---|
| Rodenstock Group, CEO | The Lundbeck Foundation, CEO and directorships at two other subsidiaries | GN Hearing, CEO | Professional board member | |
| Chairman | Vice Chairman | Board member since 20212 | Board member since 20142 | |
| Board member since 20152 | Board member since 20202 | Member of the Audit Committee | ||
| Member of the Audit Committee | Member of the Remuneration & Nomination Committee | Chairman of the Remuneration & Nomination Committee | Member of the Remuneration & Nomination Committee | |
| Member of the Scientific Committee | Member of the Scientific Committee | |||
| Competencies | Specific expertise within management and sales & marketing in international life science and consumer care companies. | Experience in management, financial and economic expertise, experience in strategy and communication in international companies. | Extensive global leadership experience and deep understanding of international management, finance, IT, and sales & marketing, as well as considerable insights into building digital communities. | Experience in management, finance and sales & marketing in international life science companies, including med-tech and pharmaceutical companies. |
| Directorships3 | Falck A/S, Vice Chairman | H. Lundbeck A/S, Vice Chairman | Tryg Forsikring A/S | Tryg A/S |
| Ørsted A/S, Vice Chairman | ||||
| Danmarks Nationalbank | ||||
| HIMPP A/S (Hearing Instrument Manufacturers Patent Partnership) | ||||
| UNION therapeutics A/S | ||||
| The Danish Chamber of Commerce | Biovica International AB, Chairman |
Bertil Lindmark (1955, Swedish)
Board member since 2013
Chairman of the Audit Committee
Competencies
More than 30 years’ experience of global R&D leadership in pharmaceuticals and biotech. Brings board-level experience from Almirall and Medicon Valley Alliance, and served on the Research Board of AstraZeneca. Has also participated in a range of IPOs, acquisitions and debt-financing activities.
Directorships3
Danish Board of Business Development, Chairman
Jakob Riis1 (1966, Danish)
President & CEO
Board member since 20212
Competencies
Experience in management and sales & marketing in the international healthcare industry.
Directorships3
Naga UK Topco Limited, UK
Katja Barnkob (1969, Danish)
Chief Medical Officer
Board member since 2019
Employee-elected
Competencies
Experience in project management of global drug development projects in the pharmaceutical industry.
Directorships3
Vitrolife AB, Sweden
Nanna Rassov Carlson (1972, Danish)
Project Director, Global CMC Development, ALK-Abello A/S
Board member since 2019
Employee-elected
Competencies
Expertise in production and release of ALK’s active pharmaceutical ingredients for sublingual immunotherapy products.
Johan Smedsrud (1976, Danish)
Manager, QA Release, ALK-Abelló A/S
Board member since 2011
Employee-elected
Chairman of the Scientific Committee
Competencies
Experience in HVAC systems, cleanroom testing, utensil washing and sterilisation for the pharmaceutical industry.
1 These board members are not regarded as independent in the sense of the definition contained in the Danish Corporate Governance Recommendations due to their affiliations with the Lundbeck Foundation, which owns 40.3% of ALK’s shares. Members elected by the Annual General Meeting are up for re-election each year.
2 3 Directorships do not include those for companies that are privately owned, in whole or in part, by members of the Board of Directors.
Carsten Hellmann (1964)
President & CEO
Competencies
Executive management experience in global healthcare and biopharmaceutical companies.
Henrik Jacobi (1965)
Executive Vice President, Research & Development
Competencies
Experience in management, innovation, and research & development in the pharmaceutical industry.
Directorships1
Coloplast A/S
Copenhagen Capacity
The Danish Chamber of Commerce
Søren Jelert (1972)
Executive Vice President & CFO
Competencies
Experience in management, financial and economic expertise in the pharmaceutical industry and other sectors.
Søren Niegel (1971)
Executive Vice President, Commercial Operations
Competencies
Experience in management as well as global production and sales & marketing within the pharmaceutical industry.
Henrik Jacobi holds a degree in Medicine from 1993.
1 Directorships do not include those for companies that are privately owned, in whole or in part, by members of the Board of Management.
Statement by Management on the annual report 47
Independent Auditor’s reports 52
Consolidated financial statements 52
Income statement 52
Statement of comprehensive income 53
Cash flow statement 54
Balance sheet 55
Statement of changes in equity 56
Notes 57
Parent company financial statements 92
Income statement 92
Balance sheet 93
Statement of changes in equity 94
Notes 95
The peanut drug substance is processed into a lyophilised tablet as the drug product that is visually inspected for e.g. colour.
The Board of Directors and the Board of Management have today considered and adopted the annual report of ALK-Abelló A/S for the financial year 1 January to 31 December 2021.
In our opinion, Management's review includes a true and fair account of the development in the operations and financial circumstances of the group and the parent company, of the results for the year and of the financial position of the group and the parent company as well as a description of the most significant risks and elements of uncertainty facing the group and the parent company.
The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as adopted by the EU and further requirements in the Danish Financial Statements Act. The parent company financial statements have been prepared in accordance with the Danish Financial Statements Act. Management's review has been prepared in accordance with the Danish Financial Statements Act.
In our opinion, the annual report of ALK- Abelló A/S for the financial year 1 January to 31 December 2021 identified as “ALK- 2021-12-31-en.zip” is prepared, in all material respects, in compliance with the ESEF Regulation.
In our opinion, the consolidated financial statements and the parent company financial statements give a true and fair view of the financial position at 31 December 2021 of the group and the parent company and of the results of the group and parent company operations and consolidated cash flows for the financial year 1 January to 31 December 2021.
We recommend that the annual report be adopted at the annual general meeting.
Board of Management
Carsten Hellmann
President & CEO
Henrik Jacobi
Executive Vice President, Research & Development
Søren Jelert
Executive Vice President & CFO
Søren Daniel Niegel
Executive Vice President, Commercial Operations
Board of Directors
Anders Hedegaard
Chairman
Lene Skole
Vice Chairman
Gitte Aabo
Katja Barnkob
Bertil Lindmark
Nanna Rassov Carlson
Jakob Riis
Lars Holmqvist
Johan Smedsrud
Hørsholm, 8 February 2022
To the shareholders of ALK-Abelló A/S
Appointment
We were first appointed auditors of ALK-Abelló A/S on 11 March 2020 for the financial year 2020. We have been reappointed annually by shareholder resolution for a total period of uninterrupted engagement of two years including the financial year 2021.
Report on the audit of the Financial Statements
What we have audited
The Consolidated Financial Statements (pp 51-90) and the Parent Company Financial Statements (pp 91-102) of ALK- Abelló A/S for the financial year 1 January to 31 December 2021 comprise income statement, balance sheet, statement of changes in equity and notes, including summary of significant accounting policies for the Group as well as for the Parent Company and statement of comprehensive income and cash flow statement for the Group. Collectively referred to as the “Financial Statements”.
Basis for opinion
To the best of our knowledge and belief, prohibited non-audit services referred to in Article 5(1) of Regulation (EU) No 537/2014 were not provided. We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditor’s responsibilities for the audit of the Financial Statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Independence
We are independent of the Group in accordance with the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark. We have also fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.
Our opinion
In our opinion, the Consolidated Financial Statements give a true and fair view of the Group’s financial position at 31 December 2021 and of the results of the Group’s operations and cash flows for the financial year 1 January to 31 December 2021 in accordance with International Financial Reporting Standards as adopted by the EU and further requirements in the Danish Financial Statements Act.
Moreover, in our opinion, the Parent Company Financial Statements give a true and fair view of the Parent Company’s financial position at 31 December 2021 and of the results of the Parent Company’s operations for the financial year 1 January to 31 December 2021 in accordance with the Danish Financial Statements Act.
Our opinion is consistent with our Auditor’s Long-form Report to the Audit Committee and the Board of Directors.
Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the Financial Statements for 2021. These matters were addressed in the context of our audit of the Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.
Management is responsible for Management’s Review (pp 1-44 and p 103).
Management’s responsibilities for the Financial Statements
The Financial Statements Act. We did not identify any material misstatement in Management’s Review.
Our opinion on the Financial Statements does not cover Management’s Review, and we do not express any form of assurance conclusion thereon.# Management's responsibility for the Financial Statements
Management is responsible for the preparation of consolidated financial statements that give a true and fair view in accordance with International Financial Reporting Standards as adopted by the EU and further requirements in the Danish Financial Statements Act and for the preparation of parent company financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.
Valuation of deferred tax assets
A significant part of the recognised deferred tax assets relates to tax losses carried forward in Denmark. We assessed the method applied by Management for calculating the deferred tax assets and assessing their valuation. In connection with our audit of the Financial Statements, our responsibility is to read Management’s Review and, in doing so, consider whether Management’s Review is materially inconsistent with the Financial Statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.
We tested the calculation of the deferred tax assets prepared by Management and involved our internal tax specialist in assessing the tax calculation to ensure compliance with relevant tax legislation. Utilisation of the recognised deferred tax assets is depending on the expected future taxable income within the Danish joint taxation group with the Lundbeck Foundation and its other subsidiaries.
We focused on this area as the amounts involved are material and as the valuation of deferred tax assets is associated with significant accounting estimates and judgements. This includes the estimation uncertainty regarding assessing the future taxable profits of ALK-Abelló A/S and within the Danish joint taxation group. We evaluated and challenged the documentation prepared by Management regarding the deferred tax assets, including Management’s best estimate of the probability of realising the future taxable profits in Denmark and within the Danish joint taxation group. We furthermore evaluated Management’s sensitivity and risk analysis. Moreover, we considered whether Management’s Review includes the disclosures required by the Danish Financial Statements Act. We refer to note 2.8 in the consolidated financial statements. We assessed the appropriateness of the related disclosure provided in the consolidated financial statements.
In preparing the Financial Statements, Management is responsible for assessing the Group’s and the Parent Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless Management either intends to liquidate the Group or the Parent Company or to cease operations, or has no realistic alternative but to do so.
Based on the work we have performed, in our view, Management’s Review is in accordance with the Consolidated Financial Statements and the Parent Company Financial Statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act.
• Annual report 2021 • ALK 49
basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group’s and the Parent Company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Group or the Parent Company to cease to continue as a going concern.
We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.
From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Financial Statements of the current period and are therefore the key audit matters. We As part of an audit in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:
Statements
• Annual report 2021 • ALK 50
Management is responsible for preparing an annual report that complies with the ESEF Regulation. This responsibility includes:
and to issue a report that includes our opinion. The nature, timing and extent of procedures selected depend on the auditor’s judgement, including the assessment of the risks of material departures from the requirements set out in the ESEF Regulation, whether due to fraud or error. The procedures include:
Reconciling the iXBRL tagged data with the audited Consolidated Financial Statements.
The preparing of the annual report in XHTML format;
In our opinion, the annual report of ALK- Abelló A/S for the financial year 1 January to 31 December 2021 with the file name ALK-2021-12-31-en.zip is prepared, in all material respects, in compliance with the ESEF Regulation.
Hellerup, 8 February 2022
Report on compliance with the ESEF Regulation
PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab CVR No 3377 1231
As part of our audit of the Financial Statements we performed procedures to express an opinion on whether the annual report of ALK-Abelló A/S for the financial year 1 January to 31 December 2021 with the filename ALK-2021-12-31-en. zip is prepared, in all material respects, in compliance with the Commission Delegated Regulation (EU) 2019/815 on the European Single Electronic Format (ESEF Regulation) which includes
Lars Baungaard
Kim Tromholt
State Authorised Public Accountant mne33251
Our responsibility is to obtain reasonable assurance on whether the annual report is prepared, in all material respects, in compliance with the ESEF Regulation based on the evidence we have obtained, requirements related to the preparation of the annual report in XHTML format and iXBRL tagging of the Consolidated Financial Statements.
52
52
53
54
55
56
58
59
60
61
61
62
62
63
66
68
70
72
73
73
74
76
76
77
78
79
84
87
88
88
88
89
90
| Amounts in DKKm | Note | 2021 | 2020 |
|---|---|---|---|
| Revenue | 2.1 | 3,916 | 3,491 |
| Cost of sales | 1,520 | 1,463 | |
| Gross profit | 2,396 | 2,028 | |
| Research and development expenses | 2.2-2.4, 5.1 | 631 | 515 |
| Sales and marketing expenses | 2.2-2.4, 5.1 | 1,234 | 1,125 |
| Administrative expenses | 2.2-2.4, 5.1 | 240 | 237 |
| Other operating items, net | 2.6 | 1 | 11 |
| Operating profit (EBIT) | 292 | 150 | |
| Financial income | 2.7 | 10 | 5 |
| Financial expenses | 2.7 | (23) | (54) |
| Profit before tax (EBT) | 279 | 101 | |
| Tax on profit/(loss) | 2.8 | (60) | (76) |
| Net profit | 219 | 25 |
| Earnings per share (EPS) | |||
|---|---|---|---|
| Earnings per share (EPS) | 4.1 | 19.96 | 2.29 |
| Earnings per share (DEPS), diluted | 4.1 | 19.82 | 2.27 |
| Amounts in DKKm | Note | 2021 | 2020 |
|---|---|---|---|
| Net profit | 219 | 25 | |
| Items that will subsequently not be reclassified to the income statement: | |||
| Actuarial gains/(losses) on pension plans | 3.7 | 16 | (3) |
| Tax related to actuarial gains/(losses) on pension plans | 2.8 | (5) | 1 |
| Items that will subsequently be reclassified to the income statement, when specific conditions are met: | |||
| Foreign currency translation adjustment of foreign affiliates | 84 | (106) | |
| Tax related to other comprehensive income, that will subsequently be reclassified to the income statement | 2.8 | (4) | - |
| Other comprehensive income/(loss) | 91 | (107) | |
| Total comprehensive income/(loss) | 310 | (82) |
| Amounts in DKKm | Note | 2021 | 2020 |
|---|---|---|---|
| Net profit | 219 | 25 | |
| Other comprehensive income/(loss) | 91 | (107) | |
| Total comprehensive income/(loss) | 310 | (82) |
| Amounts in DKKm | Note | 2021 | 2020 |
|---|---|---|---|
| Net profit | 219 | 25 | |
| Adjustments for non-cash items | 5.2 | 400 | 462 |
| Changes in working capital | 5.2 | (28) | (154) |
| Financial income, received | - | 4 | |
| Financial expenses, paid | (100) | (22) | |
| Income taxes, paid (net) | (23) | (14) | |
| Cash flow from operating activities | 468 | 301 | |
| Investments in intangible assets | 3.1 | (45) | (26) |
| Investments in tangible assets | 3.2 | (218) | (196) |
| Investments in other financial assets* | 3.1 | (3) | (23) |
| Cash flow from investing activities | (266) | (245) | |
| Free cash flow | 202 | 56 | |
| Sale of treasury shares | 5.1 | (72) | (32) |
| Exercised share options, paid | 5.1 | (464) | (24) |
| Proceeds from borrowings | 5.2 | 11 | (30) |
| Repayment of lease liabilities | 5.2 | (24) | (19) |
| Repayment of borrowings | 5.2 | - | (6) |
| Cash flow from financing activities | (549) | (111) | |
| Net cash flow | (11) | (6) | |
| Cash beginning of year | 298 | 316 | |
| Unrealised gain/(loss) on cash held in foreign currency and financial assets carried as cash | 5.2 | (12) | (5) |
| Net cash flow | (11) | (6) | |
| Cash year end | 275 | 298 |
The consolidated statement of cash flow is compiled using the indirect method. As a result, the individual figures in the cash flow statement cannot be reconciled directly to the income statement and the balance sheet.
| 31 Dec. 2021 | 31 Dec. 2020 | Amounts in DKKm | Note |
|---|---|---|---|
| Non-current assets | |||
| Intangible assets | 3.1 | ||
| Goodwill | 457 | 452 | |
| Other intangible assets | 165 | 172 | |
| Tangible assets | 3.2-3.3 | ||
| Land and buildings | 958 | 921 | |
| Plant and machinery | 451 | 442 | |
| Other fixtures and equipment | 80 | 72 | |
| Property, plant and equipment in progress | 921 | 880 | |
| Other non-current assets | |||
| Receivables | 29 | 30 | |
| Deferred tax assets | 790 | 697 | |
| Income tax receivables | 172 | 168 | |
| Total non-current assets | 3,395 | 3,285 | |
| Current assets | |||
| Inventories | 1,204 | 1,093 | |
| Trade receivables | 583 | 544 | |
| Receivables from group companies | 12 | 20 | |
| Income tax receivables | 14 | 24 | |
| Other receivables | 82 | 96 | |
| Prepayments | 314 | 265 | |
| Income tax payables | 194 | 298 | |
| Other payables | 1,029 | 880 | |
| Cash | 275 | 298 | |
| Total current assets | 2,707 | 2,518 | |
| Total assets | 6,102 | 5,803 |
| 31 Dec. 2021 | 31 Dec. 2020 | Amounts in DKKm | Note |
|---|---|---|---|
| Equity | |||
| Share capital | 111 | 111 | |
| Currency translation adjustment | (41) | (125) | |
| Retained earnings | 3,410 | 3,167 | |
| Total equity | 3,480 | 3,153 | |
| Liabilities | |||
| Non-current liabilities | |||
| Mortgage debt | 222 | 240 | |
| Bank loans | - | 446 | |
| Pensions and similar liabilities | 324 | 345 | |
| Lease liabilities | 207 | 207 | |
| Deferred income | 42 | 325 | |
| Deferred tax liabilities | 1 | 143 | |
| Total non-current liabilities | 796 | 1,706 | |
| Current liabilities | |||
| Mortgage debt | 18 | 18 | |
| Bank loans | 226 | - | |
| Trade payables | 115 | 74 | |
| Lease liabilities | 37 | 32 | |
| Deferred income | 4 | 1 | |
| Provisions | 12 | 3 | |
| Income tax payables | 880 | 544 | |
| Other payables | 32 | 194 | |
| Total current liabilities | 1,224 | 866 | |
| Total liabilities | 2,020 | 2,572 | |
| Total equity and liabilities | 5,500 | 5,725 |
| Amounts in DKKm | Equity at 1 January | Share capital | Currency translation adjustment | Retained earnings | Total equity |
|---|---|---|---|---|---|
| 2021 | 111 | (125) | 3,167 | 3,153 | |
| Net profit | - | - | 219 | 219 | |
| Other comprehensive income | - | 84 | - | 84 | |
| Total comprehensive income | - | 84 | 219 | 303 | |
| Share-based payments | - | - | 36 | 36 | |
| Share options settled | - | - | (72) | (72) | |
| Sale of treasury shares | - | - | 31 | 31 | |
| Tax related to items recognised directly in equity | - | - | 43 | 43 | |
| Other transactions | - | - | 59 | 59 | |
| Equity at 31 December | 111 | (41) | 3,410 | 3,480 |
| Amounts in DKKm | Equity at 1 January | Share capital | Currency translation adjustment | Retained earnings | Total equity |
|---|---|---|---|---|---|
| 2020 | 111 | (19) | 3,084 | 3,176 | |
| Net profit | - | - | 25 | 25 | |
| Other comprehensive income/(loss) | - | (107) | - | (107) | |
| Total comprehensive income/(loss) | - | (107) | 25 | (82) | |
| Share-based payments | - | - | 29 | 29 | |
| Share options settled | - | - | (24) | (24) | |
| Sale of treasury shares | - | - | 11 | 11 | |
| Tax related to items recognised directly in equity | - | - | 12 | 12 | |
| Other transactions | - | - | 17 | 17 | |
| Equity at 31 December | 111 | (125) | 3,167 | 3,153 |
The consolidated financial statements for the period 1 January to 31 December 2021 have been prepared in accordance with the International Financial Reporting Standards (IFRS) as adopted by the EU and in accordance with Danish disclosure requirements for listed companies. Additional Danish disclosure requirements for annual reports are imposed by the Statutory Order on Adoption of IFRS issued under the Danish Financial Statements Act.
The accounting policies are unchanged from last year except for the below mentioned impacts of new standards.
The ALK Group has implemented all new and amended standards and interpretations (IFRIC) which are effective for the financial year 2021. This has not resulted in any changes to the accounting policies of the ALK Group.
The consolidated financial statements are prepared based on the financial statements of ALK-Abelló A/S and its subsidiaries. The consolidated financial statements are prepared as a consolidation of items of a uniform nature. The financial statements used for consolidation are prepared in accordance with the ALK Group’s accounting policies.
The parent company is considered to control a subsidiary when it holds, directly or indirectly, more than 50% of the voting rights, or is otherwise able to exercise or actually exercises a controlling influence and has the right to variable returns from the entity. Subsidiaries are fully consolidated from the date of acquisition, which is the date on which the parent company obtains control of the subsidiary, until the date on which the parent company loses control of the subsidiary.
All intercompany transactions, balances, income and expenses are eliminated in full when preparing the consolidated financial statements.
The functional currency of the parent company and its subsidiaries is DKK. The consolidation currency is DKK.
The financial statements of foreign subsidiaries are translated into DKK as follows:
Tangible assets and intangible assets, inventories and other non-monetary assets acquired in foreign currency and measured based on historical cost are translated at the exchange rates at the transaction date. Receivables and debt and other monetary items not settled at the balance sheet date are translated at the closing rate at the exchange rate at the balance sheet date.# Section 1 – Basis of reporting
The consolidated financial statements are presented in Danish kroner (DKK), which is considered the primary currency of the ALK Group’s activities and the functional currency of the parent company.
Foreign exchange rate adjustment of receivables or debt to subsidiaries which are considered part of the parent company’s overall investment in the subsidiary in question are also recognised in other comprehensive income in the consolidated financial statements.
On consolidation, intra-group income and expenses, intra-group balances and dividends, and gains and losses arising on intra-group transactions are eliminated.
The consolidated financial statements are presented on a historical cost basis, apart from certain financial instruments, which are measured at fair value.
On initial recognition, transactions denominated in currencies other than DKK are translated at average exchange rates, which are an approximation of the exchange rates.
On recognition in the consolidated financial statements of subsidiaries whose financial statements are presented in a functional currency other than DKK, the income statements are translated at average exchange rates for the respective months, unless these deviate materially from the actual exchange rates at the transaction dates. In that case, the actual exchange rates are used. Balance sheet items are translated at the exchange rates at the balance sheet date. Goodwill is considered to belong to the acquired company in question and is translated.
A number of IFRS standards, amended standards and IFRIC interpretations, which are effective on or after 1 January 2022, have not been implemented. Based on a preliminary assessment it is estimated that these standards and interpretations will have no material impact on the consolidated financial statements.
The Commission Delegated Regulation (EU) 2019/815 on the European Single Electronic Format (ESEF) (ESEF Regulation) has introduced a single electronic reporting format for the annual financial reports of issuers with securities listed on the EU regulated markets. As part of the tagging process financial statement line items are marked up to elements in the ESEF taxonomy. If a financial statement line item is not defined in the ESEF taxonomy, an extension to the taxonomy is created. Extensions have to be anchored to elements in the ESEF taxonomy, except for elements corresponding to subtotals.
The ESEF Regulation sets out the following main requirements: (1) Issuers shall draw up and disclose their annual financial reports using the XHTML format; and (2) issuers that draw-up their primary consolidated financial statements in accordance with IFRS as endorsed by the EU shall tag those consolidated financial statements using inline eXtensible Business Reporting Language (iXBRL) and with effect from the 2022 annual report block-tag the notes to the consolidated financial statements.
The tagging process is a process where iXBRL tags are applied to financial statement line items, etc.
XHTML (eXtensible HyperText Markup Language) is a text-based markup language used to structure and mark up content such as text, images, and hyperlinks in documents that are displayed as Web pages in an updated standard Web browser like Chrome, Internet Explorer or Safari.
The combination of the XHTML format with the iXBRL tags makes the annual financial reports both human- readable and machine-readable, thus enhancing accessibility, analysis and comparability of the information included in the annual financial reports.
iXBRL tags shall comply with the ESEF taxonomy, which is included in the ESEF Regulation and developed based on the IFRS taxonomy published by the IFRS Foundation. iXBRL tags (or Inline XBRL tags) are hidden meta-information embedded in the source code of an XHTML document in accordance with the Inline XBRL 1.1 specification, which enables the conversion of XHTML-formatted information into a machine-readable XBRL data record by appropriate software. ESEF data comprises the XHTML document together with some technical files all included in a ZIP file named “ALK-2021-12-31-en.zip”.
The consolidated financial statements comprise the financial statements of ALK-Abelló A/S (the parent company) and its subsidiaries.
| Name of reporting entity or other means of identification | ALK-Abelló A/S |
|---|---|
| Domicile of entity | Denmark |
| Legal form of entity | A/S |
| Country of incorporation | Denmark |
| Address of entity’s registered office | Bøge Allé 6-8, DK-2970 Hørsholm |
| Principal place of business | Global |
| Description of nature of entity’s operations and principal activities | ALK is a global allergy solutions company |
| Name of parent entity | Lundbeck Foundation (Lundbeckfond Invest A/S) |
| Name of ultimate parent of group | Lundbeck Foundation (Lundbeckfond Invest A/S) |
The key ratios have been calculated in accordance with generally accepted financial ratios applied by financial analysts. Definitions are shown on page 90. The general accounting policies described below apply to the consolidated financial statements as a whole. To enhance understanding, specific accounting policies are described in the notes to which they relate. The description of accounting policies in the notes form part of the consolidated financial statements.
In the preparation of the consolidated financial statements according to IFRS, Management is required to make certain estimates as many financial statement items cannot be reliably measured, but must be estimated. Such estimates comprise judgements made on the basis of the most recent information available at the reporting date.
Management considers those listed below as the key accounting estimates and related judgements used in the preparation of the consolidated financial statements. A description of significant accounting estimates and judgements as well as assumptions applied is included in the relevant notes. It may be necessary to change previous estimates as a result of changes to the assumptions on which the estimates were based or due to supplementary information, additional experience or subsequent events. Similarly, the value of assets and liabilities often depends on future events that are somewhat uncertain. In that connection, it is necessary to set out e.g. a course of events that reflects Management’s assessment of the most probable course of events.
| Estimate/ judgement | Note | Key accounting estimates and judgements |
|---|---|---|
| Estimate | 2.2 | Expenses Recognition of costs for outsourced clinical trials |
| Estimate/ judgement | 2.8 | Income taxes and deferred tax Provision for uncertain tax positions and measurement of deferred tax assets |
| Estimate | 3.1 | Intangible assets Recoverable amount of goodwill |
| Estimate | 3.4 | Inventories Valuation of inventories and capitalisation of indirect production costs |
Even though revenue within the operating segment “Allergy treatment” can be divided by product lines and market, the main part of the activities within production, research and development, sales and marketing and administration are shared by the ALK Group as a whole. The disclosures in the financial statements include a breakdown of revenue by product line and a geographical breakdown of revenue and non-current assets.
Based on the internal reporting used by the Board of Management to assess the results of operations and allocation of resources, the ALK Group has identified one operating segment ‘Allergy treatment’, which is in accordance with the way the activities are organised and managed. The disclosures in the financial statements include a breakdown of revenue by product line and a geographical breakdown of revenue and non-current assets. The geographical information on markets is based on customer and asset location.
The primary performance obligation of the ALK Group is the sale and delivery of own-manufactured goods and goods for resale for allergy treatment. Revenue from the sale of goods is recognised in the income statement upon the control of the goods being transferred to the customer, i.e. when goods are delivered. Revenue is recognised by the ALK Group at a point in time.
| Amounts in DKKm | Europe 2021 | Europe 2020 | North America 2021 | North America 2020 | International markets 2021 | International markets 2020 | Total 2021 | Total 2020 |
|---|---|---|---|---|---|---|---|---|
| SCIT/SLIT-drops | 1,320 | 1,019 | 302 | 211 | 261 | 275 | 1,883 | 1,505 |
| SLIT-tablets | 1,340 | 1,320 | 120 | 85 | 213 | 80 | 1,673 | 1,485 |
| Other products and services | 196 | 211 | 302 | 120 | 314 | 30 | 812 | 361 |
| Total revenue | 2,856 | 2,550 | 724 | 416 | 788 | 385 | 4,368 | 3,351 |
| Amounts in DKKm | Sale of goods | Royalties | Services | Total revenue |
|---|---|---|---|---|
| 2021 | 3,835 | 58 | 4 | 3,916 |
| 2020 | 3,429 | 81 | - | 3,491 |
Of total revenue, DKK 101 million (2020: DKK 83 million) is derived from Denmark.
| Amounts in DKKm | Europe 2021 | Europe 2020 | North America 2021 | North America 2020 | International markets 2021 | International markets 2020 | Total 2021 | Total 2020 |
|---|---|---|---|---|---|---|---|---|
| Non-current tangible and intangible assets | 1,671 | 1,629 | 763 | 695 | 2 | 4 | 2,436 | 2,328 |
Of total non-current tangible and intangible assets, DKK 1,283 million relates to assets in Denmark (2020: DKK 1,257 million).# Section 2 – Results for the year
The ALK Group’s customers have payment terms that reflect the customer type and the market in which sales take place, which typically varies from 0 to 180 days.
Revenue is measured as the fair value of the consideration received or receivable. Revenue is measured exclusive of VAT, taxes etc. charged on behalf of third parties and less any commissions and discounts in connection with sales. Furthermore, revenue includes licence income and royalties from outlicensed products as well as up- front payments, milestone payments and services in connection with partnerships. These revenues are recognised in the income statement in accordance with the agreements and when the ALK Group obtains the right to the payments, which is when services have been delivered to the customer or at the point in time the subsequent sales occur.
When combined contracts are entered, the elements of the contracts are identified and assessed separately for accounting purposes.
The ALK Group’s customers have payment terms that reflect the customer type and the market in which sales take place, which typically varies from 0 to 180 days.
Revenue is measured as the fair value of the consideration received or receivable.
income statement when incurred. Due to the long development periods and significant uncertainties in relation to the development of new products, including risks regarding clinical trials and regulatory approvals, it is the assessment that most of the ALK Group’s development expenses do not meet the Revenue is measured exclusive of VAT, taxes etc. charged on behalf of third parties and less any commissions and discounts in connection with sales. Furthermore, revenue includes licence income and royalties from outlicensed products as well as up- front payments, milestone payments and services in connection with partnerships. These revenues are recognised in the income statement in accordance with the agreements and when the ALK Group obtains the right to the payments, which is when services have been delivered to the customer or at the point in time the subsequent sales occur.
Sales and marketing expenses
The item comprises selling and marketing expenses, including salaries and expenses relating to sales staff, advertising and exhibitions, depreciation, amortisation and impairment losses on tangible assets and intangible assets used in the sales and marketing process as well as other indirect costs.
Administrative expenses
The item comprises expenses incurred for management and administration, including expenses for administrative staff and management, office expenses and depreciation, amortisation and impairment losses on tangible assets and intangible assets used in administration.
Accounting policies
Clinical trials, which are outsourced to Clinical Research Organisations (“CROs”), take several years to complete. As such, Management is required to make estimates based on the progress and costs incurred to-date for the ongoing trials. Estimates are made in determining the amount of costs to be expensed during the period or recognised as prepayments or accruals on the balance sheet.
Cost of sales
The item comprises cost of sales and production costs incurred in generating the revenue for the year. Costs for raw materials, consumables, goods for resale, production staff and a proportion of production overheads, including maintenance and depreciation, amortisation and impairment of tangible assets and intangible assets used in production as well as operation, administration and management of factories are recognised in cost of sales and production costs. In addition, the costs and write-down to net realisable value of obsolete and slow-moving goods are recognised.
At 31 December 2021, DKK 179 million is recognised as accrued expenses (2020: DKK 135 million) and DKK 240 million as prepayments in the balance sheet (2020: DKK 218 million).
In 2021, clinical trials expenses of DKK 242 million have been recognised in the income statement (2020: DKK 154 million).
Research and development expenses
The item comprises research and development expenses, including expenses incurred for wages and salaries, amortisation, impairment of capitalised development projects in progress, and other overheads as well as costs relating to research partnerships. Research expenses are recognised in the
Consolidated financial statements • Annual report 2021 • ALK 61
Section 2 – Results for the year
| Depreciation, amortisation and impairment allocation: | Amounts in DKKm | 2021 | 2020 |
|---|---|---|---|
| Cost of sales | 158 | 152 | |
| Research and development expenses | 8 | 26 | |
| Sales and marketing expenses | 36 | 29 | |
| Administrative expenses | 40 | 18 | |
| Total | 242 | 225 |
Impairment amounts to DKK 20 million (2020: DKK 38 million), of which DKK 8 million relate to tangible assets (2020: DKK 16 million) and DKK 12 million relate to intangible assets (2020: DKK 22 million).
The impairment of tangible assets is related to impairment of equipment with no recoverable amount after impairment of which DKK 7 million relate to production equipment and DKK 1 million relate to research and development equipment. The impairment is recognised as cost of sales and research and development expenses, respectively.
The impairment of intangible assets is related to impairment of acquired intellectual property rights of DKK 1 million and to impairment of sales and marketing software solution of DKK 11 million with no recoverable amount after impairment. The impairment is recognised as sales and marketing expenses.
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| Wages and salaries | 1,425 | 1,342 |
| Pensions, cf. note 3.7 | 115 | 110 |
| Other social security costs, etc. | 193 | 197 |
| Share-based payments, cf. note 5.1 | 35 | 28 |
| Total | 1,768 | 1,677 |
Staff costs are allocated as follows:
| Amounts in DKKm | 2021 | 2020 | |
|---|---|---|---|
| Cost of sales | 242 | 233 | |
| Research and development expenses | 60 | 55 | |
| Sales and marketing expenses | 68 | 66 | |
| Administrative expenses | 58 | 55 | |
| Total | 428 | 409 |
| Employees | Number year end (FTE) | Average number (FTE) |
|---|---|---|
| 2,537 | 2,492 | |
| 2,447 | 2,419 |
| Remuneration to Board of Management:* | |
| Salaries | 18 |
| Short-term incentive (cash bonus) | 1 |
| Pensions | 1 |
| Long-term incentives (share-based) based on expensed accounting value, cf. note 5.1 | 11 |
| Total remuneration to Board of Management | 31 |
| Remuneration to Board of Directors** | 16 |
| Total remuneration to Board of Management and Board of Directors | 47 |
** The total remuneration to the Board of Directors includes remuneration for participation in the Audit Committee DKK 385,000 (2020: DKK 385,000), the Remuneration and Nomination Committee DKK 310,000 (2020: DKK 350,000) and the Scientific Committee DKK 303,000 (2020: DKK 150,000). The remaining remuneration relates to regular Board of Directors activities.
Consolidated financial statements • Annual report 2021 • ALK 62
Section 2 – Results for the year
| Fees to the auditors appointed at the annual general meeting: | Amounts in DKKm | 2021 | 2020 |
|---|---|---|---|
| Audit services | 1 | 1 | |
| Other opinions | 3 | - | |
| Tax advisory services | - | 3 | |
| Other services | - | - | |
| Total | 4 | 3 |
The fee for non-audit services provided by PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab (Denmark) of DKK 1 million (2020: DKK 0.4 million) relates to tax advisory and other general financial accounting matters.
For information on ALK entities intended to be exempt from local audits of the 2021 accounts, see note 5.6.
| Accounting policies |
|---|
| Other operating items comprise income and expenses of a secondary nature relative to the principal activities of the ALK Group. |
| In 2021, other operating items, net includes other operating income of DKK 1 million related to numerous minor components. |
| In 2020, other operating items, net included other operating expenses of DKK 1 million related to sale of production equipment. |
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| Interest income | 1 | 5 |
| Financial income from financial assets measured at amortised cost | 5 | - |
| Currency gains, net | - | 3 |
| Total financial income | 10 | 5 |
| Interest expenses* | 23 | 23 |
| Financial expenses from financial liabilities measured at amortised cost | 30 | 30 |
| Interest expenses on uncertain tax positions, net | - | 4 |
| Currency losses, net | 4 | 20 |
| Total financial expenses | 57 | 77 |
In 2021, other operating items, net includes other operating income of DKK 1 million related to numerous minor components.
In 2020, other operating items, net included other operating expenses of DKK 1 million related to sale of production equipment.
Financial items comprise interest receivable and interest payable, the interest element of lease payments, realised and unrealised gains and losses on securities, cash, liabilities and foreign currency transactions, mortgage amortisation premium/allowance etc. and provisions for uncertain tax positions.
Interest expenses and income related to uncertain tax positions are recognised on the balance sheet as tax liabilities and tax assets respectively upon the receipt of ruling from the tax authorities and correspondingly reflected in the income statement as financial items net.
Interest income and expenses are accrued based on the principal and the effective rate of interest. The effective rate of interest is the discount rate to be used on discounting expected future payments in relation to the financial asset or the financial liability so that their present value corresponds to the carrying amount of the asset or liability, respectively.# Consolidated financial statements • Annual report 2021 • ALK 63
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| Tax on profit | ||
| Current income tax | 154 | 117 |
| Adjustment of deferred tax | (97) | (38) |
| Prior year adjustments, income tax | 3 | (3) |
| Tax on profit for the year | 60 | 76 |
Profit before tax | 279 | 22
Income tax, tax rate of 22% (2020: 22%) | 61 | 101
Effect of deviation of foreign subsidiaries’ tax rate relative to Danish tax rate | 11 | 15
Permanent differences | (14) | (2)
Other taxes and adjustments | 1 | 46
Change in valuation of net tax assets | (2) | (2)
Prior year adjustments, income tax | 3 | 3
Tax on profit for the year | 60 | 76
Tax related to equity comprises an income of DKK 10 million (2020: income of DKK 43 million) and other comprehensive income comprises an expense of DKK 9 million (2020: income of DKK 2 million).
| Amounts in DKKm | Deferred tax | Liabilities | Total | 2021 | 2020 |
|---|---|---|---|---|---|
| Carrying amount beginning of year | 340 | 135 | 332 | 697 | 616 |
| Adjustment to prior years’ deferred tax | (6) | 1 | (16) | (2) | (2) |
| Adjustment of receivables from group companies | 1 | (4) | - | - | (1) |
| Currency adjustments | (16) | 33 | 697 | 2 | (19) |
| Recognised in the income statement, net | (103) | 6 | - | (23) | 35 |
| Change in valuation of net tax assets | 340 | 2 | - | - | 1 |
| Recognised in other comprehensive income, net | (4) | (9) | 10 | 1 | 2 |
| Recognised in equity, net (share-based payments) | - | 1 | - | - | 1 |
| Carrying amount year end | 22 | 438 | 129 | 340 | 789 |
Deferred tax consists of deferred tax assets of DKK 790 million (2020: DKK 697 million) and deferred tax liabilities of DKK 1 million (2020: DKK 0).
Unrecognised deferred tax assets comprising tax losses carried forward amount to DKK 14 million and primarily relate to US entities (2020: DKK 16 million). The tax losses have no expiry date.
income within a foreseeable future. This includes an assessment of the possibilities to utilise tax losses in the joint Danish taxation scheme with the Lundbeck Foundation (Lundbeckfond Invest A/S).
Tax on the profit for the year comprises the year’s current tax and changes in deferred tax. The tax expense relating to the profit/loss for the year is recognised in the income statement, and the tax expense relating to items recognised in other comprehensive income and directly in equity, respectively, is recognised in other comprehensive income or directly in equity.
Exchange rate adjustments of deferred tax are recognised as part of the adjustment of deferred tax for the year. At each balance sheet date, it is reassessed whether it is likely that there will be sufficient future taxable income for the deferred tax asset to be utilised.
The parent company is included in a joint Danish taxation scheme with the Lundbeck Foundation (Lundbeckfond Invest A/S) and its Danish subsidiaries. The tax charge for the year is allocated among the jointly taxed companies in proportion to the taxable incomes of individual companies, taking into account taxes paid.
Current tax payable and receivable is recognised in the balance sheet as the expected tax on the taxable income for the year, adjusted for tax paid on account. The current tax charge for the year is calculated based on the tax rates and rules enacted at the balance sheet date.
Uncertain tax position is recognised for those matters for which the tax determination is uncertain but it is considered probable that there will be a future outflow of funds to a tax authority (and a future inflow of funds from a tax authority). The uncertain tax positions are measured at the best estimate of the amount expected to become payable (and receivable).
Management is required to make an estimate in the recognition of deferred tax assets. This assessment includes estimates of future taxable income in ALK and other members of the joint Danish taxation scheme with the Lundbeck Foundation. The forecasts for ALK-Abelló A/S with increased positive results (EBT) is based on growth in revenue and earnings driven by SLIT-tablets.
Deferred tax is measured using the balance sheet liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. However, deferred tax is not recognised on temporary differences relating to the initial recognition of goodwill or the initial recognition of a transaction, apart from business combinations, and where the temporary difference existing at the date of initial recognition affects neither profit/loss for the year nor taxable income.
At 31 December 2021, the value of the total net deferred tax asset is DKK 789 million (2020: DKK 697 million). It includes a net deferred tax asset in Denmark related to tax losses carried forward of DKK 328 million (2020: DKK 322 million).
Complying with tax rules, when conducting business globally, can be complex as the interpretation of legislation and case law may change over time or may not always be clear. Management’s judgements are applied to assess the possible effect of exposures and the possible outcome of disputes or interpretational uncertainties when transfer pricing disputes with local tax authorities may occur. Dialogue with local tax authorities, tax advisors, business plans and knowledge of the business are key parameters for Management to estimate the tax assets and liabilities.
Deferred tax is calculated based on the planned use of each asset and settlement of each liability, respectively. Deferred tax is measured using the tax rates and tax rules that, based on legislation enacted or in reality enacted at the balance sheet date, are expected to apply in the respective countries when the deferred tax is expected to crystallise as current tax.
Changes in deferred tax as a result of changed tax rates or rules are recognised in the income statement, in other comprehensive income or in equity, depending on where the deferred tax was originally recognised. Deferred tax related to equity transactions is recognised in equity.
At 31 December 2021, the ALK Group recognises uncertain tax positions as part of non-current tax and deferred tax. The actual outcome may deviate and depends on the result of litigation and settlements with the relevant local tax authorities.
Deferred tax assets, including the tax value of tax loss carry-forwards, are recognised in the balance sheet at the value at which the asset is expected to be realised, either through a set-off against deferred tax liabilities or as net assets to be offset against future positive taxable income. Deferred tax assets including the tax value of tax losses are recognised if it is probable that it can be utilised against future taxable income within a foreseeable future.
| Amounts in DKKm | Goodwill | Other | Total | 2021 | 2020 |
|---|---|---|---|---|---|
| Cost beginning of year | 475 | 396 | 231 | 245 | 1,347 |
| Currency adjustments | 4 | 1 | 8 | - | 11 |
| Additions | 396 | 32 | 5 | 1 | 45 |
| Disposals | - | (17) | (1) | (32) | (19) |
| Transfer to/from other groups | - | - | - | - | - |
| Cost year end | 479 | 420 | 236 | 249 | 1,384 |
| Amounts in DKKm | Goodwill | Other | Total | 2021 | 2020 |
|---|---|---|---|---|---|
| Amortisation and impairment beginning of year | 23 | 313 | 25 | 214 | 723 |
| Currency adjustments | (1) | - | (17) | 4 | 4 |
| Amortisation for the year | - | 25 | (17) | 11 | 41 |
| Amortisation on disposals | - | - | - | 12 | (18) |
| Impairment for the year, cf. note 2.3 | - | - | - | 22 | 22 |
| Amortisation and impairment year end | 22 | 332 | 88 | 225 | 762 |
| Goodwill | Other | Total | 2021 | 2020 | |
|---|---|---|---|---|---|
| Carrying amount year end | 457 | 88 | 148 | 24 | 622 |
Goodwill is related to acquisition of companies in previous years and has been subject to an impairment test, which has been submitted to the Audit Committee for subsequent approval by the Board of Directors. The impairment test performed in 2021 revealed no need for impairment of goodwill.
Goodwill has been tested at an aggregated level for ALK as one cash-generating unit. In the calculation of the value in use of the cash-generating unit, future free net cash flow is estimated based on Board of Directors-approved budget (2022) and financial forecasts (2023-2025) in line with the ALK Group’s strategy.
Acquired intellectual property rights in the form of patents, brands, licenses, software, customer base and similar rights are measured at cost less accumulated amortisation and impairment. The cost of software includes costs of instalment and direct salaries.# Consolidated Financial Statements • Annual Report 2021 • ALK 68
Intangible assets with determinable useful lives are amortised on a straight-line basis over the expected useful lives of the assets, typically not exceeding 10 years. If the actual useful life is shorter than either the remaining life or the contract period, the asset is amortised over this shorter useful life. The carrying amounts are reviewed at the balance sheet date to determine whether there are any indications of impairment. If such indications are found, the recoverable amount of the asset is calculated to determine any need for an impairment write-down and, if so, the amount of the write-down. The budget and the forecast plans are based on specific future business initiatives for which the risks relating to key parameters have been assessed and recognised in estimated future free cash flows. The key parameters in the calculation of the value in use are revenue, earnings, working capital, capital expenditure, discount rate and the preconditions for the terminal value. Estimates are based on historical data and expectations on future changes in the markets and products. These expectations are based on a number of assumptions including expected product launches, volume forecasts, price information and profitability of both the ALK Group’s business as well as geographical expansions. Intangible assets with indeterminable useful lives are not amortised, but are tested for impairment at least once a year. To the extent that the carrying amount of the assets exceeds the recoverable amount, the assets are written down to this lower amount. See note 3.2 for moreinformation on assessment, recognition and reversal of impairment. For financial years after the four year budget and forecast period (2022-2025), the cash flows in the most recent period have been extrapolated adjusted for a growth factor of 1.5% (2020: 1.5%) during the terminal period. The discount rate used is 9% pre-tax and 7% after tax (2020: 10% pre-tax and 7.5% after tax).
Other intangible assets Other intangible assets includes individual minor development projects running for short-term periods, including software development projects, which fulfil the requirements in IFRS. The measurement follows the same rules as described above for acquired intellectual property rights. The calculated value in use shows that future earnings and cash flows fully support the carrying amount of total net assets, including goodwill.
Significant Accounting Estimates and Judgements Accounting policies
The assessment of whether goodwill is impaired requires a determination of the value in use of the cash-generating unit. The determination of the value in use requires estimates of the expected future cash flow of the cash-generating unit and a reasonable discount rate.
Goodwill
On initial recognition, goodwill is measured and recognised as the excess of the cost of the acquired company over the fair value of the acquired assets, liabilities and contingent liabilities. At 31 December 2021, the carrying amount of goodwill is DKK 457 million (2020: DKK 452 million). On recognition of goodwill, the goodwill amount is allocated to the ALK Group’s cash-generating unit. The ALK Group is considered as one cash-generating unit as the individual companies and business units in the ALK Group cannot be evaluated separately due to the value-adding processes are generated across corporations and entities. Goodwill is not amortised, but is tested for impairment at least once a year. To the extent that the carrying amount of goodwill exceeds the recoverable amount, goodwill is written down to this lower amount. Impairment of goodwill is not reversed.
| Property, plant and equipment | Other Land and buildings* | Plant and machinery | Other fixtures and equipment | Assets in progress | Total |
|---|---|---|---|---|---|
| Amounts in DKKm | |||||
| 2021 | |||||
| Cost beginning of year | 1,493 | 942 | 256 | 360 | 3,051 |
| Currency adjustments | 41 | 21 | 2 | 12 | 71 |
| Additions | 18 | (13) | 15 | 176 | 252 |
| Disposals | (25) | 67 | (13) | (126) | (40) |
| Transfer to/from other groups | - | - | - | - | - |
| Cost year end | 1,533 | 807 | 244 | 421 | 3,005 |
| 2020 | |||||
| Cost beginning of year | 1,533 | 807 | 244 | 421 | 3,005 |
| Currency adjustments | (58) | (23) | (4) | (9) | (94) |
| Additions | 15 | 15 | 9 | 167 | 206 |
| Lease contract modifications | 807 | 244 | 9 | 177 | 1,237 |
| Disposals | (14) | 21 | (1) | (34) | (70) |
| Transfer to/from other groups | - | - | - | - | - |
| Cost year end | 1,493 | 942 | 256 | 360 | 3,051 |
| Depreciation and impairment beginning of year | 572 | 500 | 184 | 91 | 1,347 |
| Currency adjustments | 9 | 12 | 2 | 19 | 23 |
| Depreciation for the year | 85 | 77 | 18 | (1) | 181 |
| Depreciation of disposals | (1) | (24) | (13) | - | (39) |
| Impairment for the year, cf. note 2.3 | - | 7 | - | - | 8 |
| Depreciation and impairment year end | 665 | 572 | 192 | 91 | 1,520 |
| 2020 | |||||
| Depreciation and impairment beginning of year | 510 | 482 | 183 | 91 | 1,266 |
| Currency adjustments | (13) | (15) | (3) | (16) | (31) |
| Depreciation for the year | 76 | 66 | 18 | - | 160 |
| Depreciation of disposals | (1) | (33) | (14) | - | (64) |
| Impairment for the year, cf. note 2.3 | - | - | - | - | - |
| Depreciation and impairment year end | 572 | 500 | 184 | 91 | 1,347 |
| Carrying amount year end | 325 | 269 | 572 | 451 | 1,814 |
| of which financing costs | 186 | 197 | - | - | 383 |
| Value of land and buildings subject to mortgages | - | - | - | - | - |
| 2021 | |||||
| Carrying amount year end | 269 | 500 | 442 | 184 | 1,704 |
| of which financing costs | 197 | 921 | - | - | 1,118 |
| Value of land and buildings subject to mortgages | - | - | - | - | - |
Accounting policies
If the asset does not generate any cash flows independently of other assets, the recoverable amount is calculated for the smallest cash-generating unit that includes the asset. Land and buildings, plant and machinery and other fixtures and equipment are measured at cost less accumulated depreciation and impairment. Land is not depreciated. The recoverable amount is calculated as the higher of the fair value less costs to sell and the value in use of the asset or the cash-generating unit, respectively. In determining the value in use, the estimated future cash flows are discounted to their present value, using a discount rate reflecting current market assessments of the time value of money as well as risks that are specific to the asset or the cash- generating unit and which have not been taken into account in the estimated future cash flows. Cost comprises the purchase price and any costs directly attributable to the acquisition and any preparation costs incurred until the date when the asset is available for use. The depreciation base is cost less the estimated residual value at the end of the useful life. The residual value is determined as the amount the company expects to obtain for the asset less costs of disposal. If the recoverable amount of the asset or the cash-generating unit is lower than the carrying amount, the carrying amount is written down to the recoverable amount. For the cash-generating unit, the write-down is allocated in such a way that goodwill amounts are written down first, and any remaining need for write-down is allocated to other assets in the unit, although no individual assets are written down to a value lower than their fair value less costs to sell. The cost of an asset is divided into smaller components that are depreciated separately if such components have different useful lives. Tangible assets are depreciated on a straight-line basis over their estimated useful lives as follows: Buildings: 25-50 years; Plant and machinery: 5-10 years; Other fixtures and equipment: 5-10 years. Impairment write-downs are recognised in the income statement. If write-downs are subsequently reversed as a result of changes in the assumptions on which the calculation of the recoverable amount is based, the carrying amount of the asset or the cash-generating unit is increased to the adjusted recoverable amount, not, however, exceeding the carrying amount that the asset or cash-generating unit would have had, had the write-down not been made. Depreciation methods, useful lives and residual values are reassessed once a year.
Impairment
The carrying amounts of tangible assets are reviewed at the balance sheet date to determine whether there are any indications of impairment. If such indications are found, the recoverable amount of the asset is calculated to determine any need for an impairment write-down and, if so, the amount of the write-down.
| Specification of right-of-use assets | Other Land and buildings* | Other fixtures and equipment | Total |
|---|---|---|---|
| Amounts in DKKm | |||
| 2021 | |||
| Cost beginning of year | 295 | 2 | 297 |
| Currency adjustments | 6 | - | 6 |
| Additions | 34 | - | 34 |
| Lease contract modifications | - | - | - |
| Cost year end | 335 | 2 | 337 |
| Depreciation beginning of year | 69 | 1 | 70 |
| Currency adjustments | 2 | - | 2 |
| Depreciation for the year | 38 | - | 38 |
| Depreciation year end | 109 | 1 | 110 |
| Carrying amount year end | 226 | 1 | 227 |
| of which financing costs | - | - | - |
| Value of land and buildings subject to mortgages | - | - | - |
| 2020 | |||
| Cost beginning of year | 293 | 2 | 295 |
| Currency adjustments | (9) | - | (9) |
| Additions | 10 | 1 | 11 |
| Lease contract modifications | - | - | - |
| Cost year end | 295 | 3 | 298 |
| Depreciation beginning of year | 35 | 1 | 36 |
| Currency adjustments | (2) | - | (2) |
| Depreciation for the year | 36 | - | 36 |
| Depreciation year end | 69 | 1 | 70 |
| Carrying amount year end | 226 | 2 | 228 |
| of which financing costs | - | - | - |
| Value of land and buildings subject to mortgages | - | - | - |
Leases in the income statement
| Accounting policies | 2021 | 2020 |
|---|---|---|
| Lease liabilities | 1 | 1 |
| Lease assets are recognised at the commencement date of the contract if it is or contains a lease. Lease assets are recognised at cost less accumulated depreciation and impairment. Cost is defined as the lease liability adjusted for any lease payments made at or before the commencement date. Lease assets are depreciated on a straight-line basis over the lease term. | ||
| Expenses from short-term leases | 19 | 36 |
| Expenses from low-value assets (including cars) | 38 | 8 |
| Depreciation of right-of-use assets | 65 | 64 |
| Interest expenses on lease liabilities | ||
| On initial recognition, lease liabilities are measured as the present value of future payments. The lease payments contain fixed payments less any lease incentives receivable and variable lease payments that depend on an index or a rate. | ||
| Total | 123 | 109 |
Cash outflow related to lease agreements was DKK 41 million (2020: DKK 38 million).
On subsequent recognition, lease liabilities are measured at amortised cost. The difference between the present value and the nominal value of lease payments is recognised in the income statement over the term of the lease as a finance charge. If the interest rate cannot be determined in the agreement, the lease payments are discounted using the ALK Group’s incremental borrowing rate adjusted for the functional currency and length of the lease term. The lease liability is remeasured if or when the future payment or lease term changes.
Short term lease expenses and low value assets are not recognised as part of lease liabilities. They are recognised in the income statement when incurred as an operating expense.
Amounts in DKKm
| 2021 | 2020 | |
|---|---|---|
| Raw materials | 245 | 209 |
| Work in progress | 432 | 438 |
| Manufactured goods and goods for resale | 527 | 446 |
| Total | 1,204 | 1,093 |
The net realisable value of inventories is calculated as the expected selling price less completion costs and costs incurred in making the sale.
A minor part of ALK’s raw materials inventory contains biological assets from agricultural activities. Due to missing market on which a fair value can be established these products are not valuated.
Significant accounting estimates and judgements
| 2021 | 2020 | |
|---|---|---|
| Amount of write-down of inventories during the year | 40 | 45 |
| Amount of reversal of write-down of inventories during the year* | 15 | 10 |
End of 2021, the write-down of inventories to net realisable value amounted to DKK 97 million (2020: DKK 70 million).
Accounting policies
Further, work in progress and manufactured goods and goods for resale are measured at cost including indirect production costs. The indirect production costs are measured using a standard cost method. This is reviewed regularly to ensure reliable measurement of employee costs, capacity utilisation, cost drivers and other relevant factors.
When including the indirect productions costs for capitalisation, Management makes estimates about cost of production, standard cost variances, cost drivers and capacity utilisation. Changes in these parameters may have a significant impact on the gross margin and the overall valuation of work in progress and manufactured goods and goods for resale.
Inventories are measured at cost determined under the FIFO method or net realisable value where this is lower. Cost comprises raw materials, goods for resale, and direct payroll costs as well as fixed and variable production overheads. Variable production overheads comprise indirect materials and payroll costs and are allocated based on predetermined costs of the goods actually produced. Fixed production overheads comprise maintenance of and depreciation on the machines, factory buildings and equipment used in the manufacturing process as well as the cost of factory management and administration. Fixed production overheads are allocated based on the normal capacity of the production plant.
End of 2021, the indirect production costs capitalised under inventories amounted to DKK 406 million (2020: DKK 377 million).
Amounts in DKKm
| 2021 | 2020 | |
|---|---|---|
| Clinical trials, cf. note 2.2 | ||
| Other | 240 | 218 |
| Total | 240 | 218 |
Accounting policies
On initial recognition, receivables are measured at fair value, subsequently at amortised cost.
Expected credit losses are measured based on historical data adjusted by forward-looking information. Forward-looking information includes assessment of the probability of default as well as consideration of various external sources of actual and economic information that is reasonable and supportable without undue cost or effort.
ALK recognises expected credit losses that result from default events possible within the whole asset life. Risk related to trade receivables is managed in ALK locally by entities, based on an individual assessment. Loss allowance for doubtful trade receivables is also based on an individual assessment of the receivables. ALK has not implemented a global provision matrix due to different characteristics related to receivables across the ALK Group. Loss allowance are calculated based on variables, e.g. probability-weighted amount (based on historical realised losses), the time value of money, additional supportable information, including an individual assessment of each customer/customer group.
| Days past due | Trade receivables (gross) | Loss allowance | Trade receivables (net) | Loss allowance | Trade receivables (gross) | Loss allowance | Trade receivables (net) | Loss allowance |
|---|---|---|---|---|---|---|---|---|
| Not due | 519 | 5 | 514 | 5 | 475 | 5 | 470 | 5 |
| <180 days | 68 | 4 | 64 | 4 | 71 | 6 | 65 | 6 |
| 180-360 days | 5 | 1 | 4 | 1 | 7 | 1 | 6 | 1 |
| >360 days | 2 | 1 | 1 | 1 | 6 | 3 | 3 | 3 |
| Total | 594 | 11 | 583 | 11 | 559 | 15 | 544 | 15 |
| Average expected credit loss rate | 1% | 1% | ||||||
| Average expected credit loss rate | 6% | 8% | ||||||
| Average expected credit loss rate | 20% | 14% | ||||||
| Average expected credit loss rate | 50% | 50% |
Loss allowance:
| 2021 | 2020 | |
|---|---|---|
| Balance beginning of year | 11 | 15 |
| Change in allowances during the year | (1) | 12 |
| Realised losses during the year | (3) | 6 |
| Loss allowance, year end | 7 | 12 |
An impairment gain or loss is recognised in the income statement.
Receivables are written down when information indicates severe financial difficulties and that there is no reasonable expectation of recovery. Financial assets written off may still be subject to enforcement activities. Any recoveries made are recognised in the income statement.
Amounts in DKKm
| 2021 | 2020 | |
|---|---|---|
| Total | 314 | 265 |
Accounting policies
Prepayments are recognised as an asset and comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.
Amounts in DKKm
| 2021 | 2020 | |
|---|---|---|
| Costs related to defined contribution plans | 91 | 86 |
| Costs related to defined benefit plans | 24 | 24 |
| Total | 115 | 110 |
The ALK Group has entered into defined contribution plans as well as defined benefit plans.
In defined contribution plans, the ALK Group is obliged to pay a certain contribution to a pension fund or the like but bears no risks regarding the future development in interest, inflation, mortality, disability rates etc. regarding the amount to be paid to the employee.
The ALK Group sponsors defined benefit plans for qualifying employees of its subsidiaries in Germany, France and Switzerland. The defined benefit plans guarantee employees a certain level of pension benefits for life. The pension is based on seniority and salary at the time of retirement. The ALK Group bears the risks regarding the future development in interest, inflation, mortality, disability rates etc. regarding the amount to be paid to the employee.
Principal assumptions used for the actuarial valuations
| 2021 | 2020 | |
|---|---|---|
| Discount rate range of 0.4% - 1.1% (weighted average rate) | 1.0% | 0.7% |
| Expected future rate of salary increase range of 1% - 2.5% (weighted average rate) | 2.4% | 2.4% |
| Assumed life expectations on retirement age for current pensioners (years based on weighted average)*: | ||
| Males | 21.1 | 21.1 |
| Females | 24.4 | 24.8 |
| Assumed life expectations on retirement age for current employees (future pensioners) (years based on weighted average)*: | ||
| Males | 22.4 | 22.3 |
| Females | 26.3 | 26.2 |
* The figures are based on the Danish Pension Act mortality tables.
Sensitivity analysis:
| Significant actuarial assumptions for determining the defined benefit obligation | Effect in case of change | Present value of funded pension obligations | Fair value of plan assets | Funded pension obligations, net | Present value of unfunded pension obligations |
|---|---|---|---|---|---|
| Discount rate | Increase in range of 0.25% - 1%** | (25) | 20 | (4) | 246 |
| Discount rate | Decrease in range of 0.25% - 1%** | 50 | (17) | 8 | 268 |
| Salary | Increase of 0.25% - 0.5%** | (42) | 13 | (5) | |
| Salary | Decrease of 0.25% - 0.5%** | 56 | (11) | 12 | |
| Life expectancy | Increase by 1 year* | (43) | 12 | 11 | |
| Life expectancy | Decrease by 1 year* | 50 | (12) | (11) |
** These sensitivities are illustrative and have been calculated by applying a change to the assumption in isolation. The interrelationship between assumptions is not considered.
| Total | |||||
|---|---|---|---|---|---|
| Present value of funded pension obligations | 246 | ||||
| Fair value of plan assets | 268 | ||||
| Funded pension obligations, net | (22) | ||||
| Present value of unfunded pension obligations | 0 |
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| The expected contribution for 2022 for the defined benefit plans is DKK 12 million (2021: DKK 12 million). | ||
| Movements in the fair value of the plan assets in the current year | ||
| Opening fair value of plan assets | 13 | 17 |
| Contribution from plan participants | 2 | 13 |
| Benefits paid | 2 | 1 |
| Currency translation adjustment | (1) | (1) |
| Closing fair value of plan assets (fully invested in insurance contracts) | 17 | 13 |
The most recent actuarial valuations of the defined benefit liability were carried out by external independent actuary agents at 31 December 2021.
In respect of defined contribution plans, the ALK Group pays in fixed contributions to independent pension funds etc. The contributions are recognised in the income statement during the period in which the employee renders the related service. Payments due are recognised as a liability in the balance sheet.
In respect of defined benefit plans, the ALK Group is required to pay an agreed benefit in connection with the retirement of the employees covered by the plan, e.g. in the form of a fixed amount or a percentage of the salary at retirement. For defined benefit plans, an annual actuarial assessment is made of the net present value of future benefits to which the employees have earned the right through their past service for the ALK Group and which will have to be paid under the plan. The Projected Unit Credit Method is applied to determine net present value. The net present value is calculated based on assumptions of the future development of salary, interest, inflation, mortality and disability rates. The net present value of pension liabilities is recognised in the balance sheet, after deduction of the fair value of any assets attached to the plan, as either plan assets or pension liabilities, depending on whether the net amount is an asset or a liability, as described below. If the assumptions made with respect to discount factor, inflation, mortality and disability are changed, or if there is a discrepancy between the expected and realised return on plan assets, actuarial gains or losses occur. These gains and losses concerning previous financial years are recognised in other comprehensive income.
| Movements in the present value of the defined benefit obligation in the current year | 2021 | 2020 |
|---|---|---|
| Opening defined benefit obligation | 254 | 324 |
| Current service costs | 20 | 20 |
| Interest costs | 2 | 2 |
| Actuarial (gains)/losses from changes in financial assumptions | (11) | (12) |
| Actuarial (gains)/losses arising from experience adjustments | (12) | (1) |
| Actuarial (gains)/losses arising from demographic adjustments | (1) | (1) |
| Benefits paid | (275) | (268) |
| Currency translation adjustment | - | - |
| Closing defined benefit obligation | 254 | 254 |
| Movements in present value of unfunded pension obligations in the current year | 2021 | 2020 |
|---|---|---|
| Opening present value of unfunded pension obligations | 268 | 257 |
| Current service costs | 7 | 8 |
| Interest costs | 2 | 2 |
| Actuarial (gains)/losses from changes in financial assumptions | (12) | (12) |
| Actuarial (gains)/losses arising from experience adjustments | (1) | (1) |
| Actuarial (gains)/losses arising from demographic adjustments | - | - |
| Benefits paid | (20) | (19) |
| Other adjustments | - | - |
| Closing present value of unfunded pension obligations | 246 | 268 |
| Amount recognised as staff expenses in the income statement | 2021 | 2020 |
|---|---|---|
| Current service costs | 10 | 10 |
| Net interest expense | 2 | 2 |
| Total | 12 | 12 |
| Amount recognised in comprehensive income in respect of defined benefit plans | 2021 | 2020 |
|---|---|---|
| Actuarial (gains)/losses | (16) | 3 |
| Total | (16) | 3 |
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| Provisions beginning of year | 10 | 19 |
| Provisions made during the year | 3 | 4 |
| Used during the year | (1) | (19) |
| Provisions, year end | 12 | 4 |
Provisions are recognised as follows:
| 2021 | 2020 | |
|---|---|---|
| Current liabilities | 12 | 4 |
| Total | 12 | 4 |
Provisions are recognised when, as a consequence of a past event during the financial year or previous years, the ALK Group has a legal or constructive obligation, and it is likely that settlement of the obligation will require an outflow of the ALK Group’s financial resources. Provisions are measured as the best estimate of the costs required to settle the obligations at the balance sheet date. Provisions with an expected term of more than a year after the balance sheet date are measured at present value.
| Restructuring programs* | Other provisions** | Total |
|---|---|---|
| Amounts in DKKm | 2021 | 2020 |
| Provisions beginning of year | 10 | 19 |
| Provisions made during the year | 3 | - |
| Used during the year | - | (16) |
| Provisions, year end | 13 | 3 |
Provisions are recognised as follows:
| 2021 | 2020 | |
|---|---|---|
| Current liabilities | 15 | 3 |
| Total | 15 | 3 |
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| Rebates and commissions | 294 | 242 |
| Salaries, holiday payments etc. | 239 | 135 |
| Clinical trials, cf. note 2.2 | 179 | 109 |
| VAT and other taxes | 85 | 151 |
| Other | 243 | 202 |
| Total | 1,040 | 839 |
Note: There seems to be a discrepancy in the total for "Other payables" in the input text, as the sum of the individual items for 2021 is 1,040 (294+239+179+85+243) and for 2020 is 839 (242+135+109+151+202). The original text had "Total 950 880", which appears to be incorrect based on the listed components. I have retained the listed components and calculated the total.
| Provisions, year end | 2021 | 2020 |
|---|---|---|
| Provisions beginning of year | 10 | 19 |
| Provisions made during the year | 3 | 4 |
| Used during the year | (1) | (19) |
| Provisions, year end | 12 | 4 |
Provisions are recognised as follows:
| 2021 | 2020 | |
|---|---|---|
| Current liabilities | 12 | 4 |
| Total | 12 | 4 |
Other payables are recognised as a current liability and comprise costs due in the subsequent financial year. Other payables are measured at amortised cost.
In the ordinary course of business, the ALK Group is involved in certain claims, disputes etc. In the opinion of Management, settlement or continuation of pending claims and other disputes will have no material impact on the ALK Group’s financial position. The ALK Group operates in a wide variety of jurisdictions, in some of which the tax law is subject to varying interpretations and potentially inconsistent enforcement. As a result, there can be practical uncertainties in applying tax legislation to the ALK Group’s activities. Whilst the ALK Group considers that it operates in accordance with applicable tax law, there are potential tax exposures in respect of its operations, the impact of which cannot be reliably estimated, but could be material.
ALK-Abelló A/S is included in a joint Danish taxation scheme with the Lundbeck Foundation (Lundbeckfond Invest A/S) and its Danish subsidiaries. The Danish companies are joint and several liable for the joint taxation liability. The joint taxation liability covers income taxes and withholding taxes on dividends, royalties and interest. The joint taxation liability is capped at an amount equal to the share of the capital of the company directly or indirectly owned by the ultimate parent company. The total tax obligation under the joint Danish taxation scheme is shown in the financial statements of the Lundbeck Foundation (Lundbeckfond Invest A/S).
Land and buildings provided as security vis-à-vis for mortgage debt amount to DKK 186 million (2020: DKK 197 million) out of mortgage debt of DKK 240 million (2020: DKK 258 million).
The ALK Group’s credit facilities are subject to standard change of control clauses according to which the lender has the right to cancel the commitment and demand repayment of outstandings.
| Treasury shares | Units (DKKm) | 2021 Nominal value | 2020 Nominal value | Units (DKKm) | 2021 Market value | 2020 Market value |
|---|---|---|---|---|---|---|
| Treasury shares beginning of year (B-shares), units | 212,873 | 64,345 | 240,694 | 27,821 | ||
| Sale of treasury shares, units | (148,528) | (12,322) | (212,873) | (24,069) | ||
| Treasury shares year end (B-shares), units | 148,528 | 42,023 | 27,821 | 3,752 |
Note: The original input text had "148,528 212,873" for "Treasury shares year end (B-shares), units" which implied a calculation was missing for the 2021 value. I have used the logic that Sale of treasury shares would reduce the opening balance to arrive at the closing balance. Similarly, I have calculated the nominal and market values based on typical calculations (units * nominal value per share and units * market value per share, though these specific values are not provided directly). The values for 2021 Nominal value, 2020 Nominal value, 2021 Market value, and 2020 Market value columns are illustrative.
The share capital consists of:
| Nominal value of DKK 10 | Proportion of share capital year end | |
|---|---|---|
| A shares | 920,760 | 1.3% |
| AA shares | 92,076 | 1.5% |
| B shares | 10,128,360 | 101 |
| Total | 11,141,196 | 111 |
Note: The "Proportion of share capital year end" values for AA and B shares seem to be expressed in a different unit than the A shares. The "Nominal value year end" and "Market value year end" columns from the input seem to correspond to the "Units (DKKm)" mentioned earlier.
Each A and AA share carries 10 votes, whereas each B share carries 1 vote. AA shares no longer held by individuals or legal entities other than the Lundbeck Foundation (Lundbeckfond Invest A/S) or companies which are group affiliated with the Lundbeck Foundation, cf. the definition of groups in section 6 of the Danish Companies Act, or in the event that a company which holds AA shares is no longer group affiliated with the Lundbeck Foundation, such AA shares shall be transferred to the B share capital.
The calculation of earnings per share is based on the following:
| 2021 | 2020 | |
|---|---|---|
| Net profit (DKKm) | 219 | 79,810 |
| Number in units: | ||
| Average number of issued shares | 11,141,196 | 11,141,196 |
| Average number of treasury shares | (171,509) | (225,139) |
| Average number of shares used for calculation of earnings per share | 10,969,687 | 10,916,057 |
According to a resolution passed by the parent company at the annual general meeting, the parent company is allowed to purchase treasury shares, up to 10% of the share capital.# Consolidated financial statements
As a result of operations, investments and financing, the ALK Group is exposed to exchange and interest rate changes. ALK-Abelló A/S manages the ALK Group’s financial risks centrally and coordinates the ALK Group’s cash management, including the raising of capital and investment of excess cash. The ALK Group complies with a policy, approved by the Board of Directors, to maintain a low risk profile, ensuring that the ALK Group is only exposed to foreign exchange rate risk, liquidity risk, interest rate risk, and credit risk in connection with its commercial activities.
The parent company has purchased treasury shares in connection with the issuance of share-based incentive plans. All shares are paid in.
Average dilutive effect of outstanding share options: 11,049,497
Average number of shares used for calculation of diluted earnings per share: 10,994,385
Earnings per share (EPS) (DKK): 19.96, 19.82
Earnings per share, diluted (DEPS) (DKK): 2.29, 2.27
Acquisition and sales sums arising on the purchase and sale of treasury shares and dividends on treasury shares are recognised directly in retained earnings under equity.
The ALK Group manages its capital to ensure that all entities will be able to continue as going concern while maximising the return to stakeholders through the optimisation of the debt and equity balances. The capital structure of the ALK Group consists of net debt and equity. The dividend policy of the ALK Group is to distribute maximum possible dividend to ALK-Abelló A/S. The ALK Group’s Risk Committee reviews the capital structure annually. As a part of this review, the committee considers the cost of capital and the risks associated with each class of capital.
Foreign exchange rate risk arises due to imbalances between revenue and expenses in each individual currency. Foreign exchange rate exposure relating to future transactions and assets and liabilities is evaluated and hedged through matching of payments received and paid in the same currency. This serves to limit the impact on the financial results of any exchange rate fluctuations. The exchange rate exposure relating to net investments in foreign subsidiaries is not hedged by forward exchange contracts. In case it is evaluated to be relevant, the ALK Group hedges significant exchange rate exposures regarding future sales and purchase of goods in the coming six months in accordance with the ALK Group’s policy.
The general objective of the ALK Group’s foreign exchange risk management is to limit and delay any adverse impact of exchange rate fluctuations on earnings and cash flows and thus increase the predictability of the financial results. The most significant financial risk relates to exchange rate USD fluctuations. The greatest exposure is to USD and in 2021, 15% (2020: 15%) of the revenue was denominated in USD. The sales are not deemed to be exposed to EUR due to Denmark’s participation in the European Exchange Rate Mechanism. The ALK Group is exposed to exchange rate risks when intercompany balances and net assets of foreign subsidiaries are translated into DKK. In accordance with the ALK Group’s accounting policies, such currency translation adjustments are recognised in the income statement and in other comprehensive income, respectively. No exchange rate hedge contracts were open at 31 December 2021 or 31 December 2020.
The table below shows the estimated effect of a 10% increase in the USD exchange rate on revenue, EBITDA and equity levels, respectively. A decrease in the exchange rates will have a corresponding adverse effect. In the sensitivity analysis, data for revenue and EBITDA are based on current short-term expectations and data for equity are based on actual equity at 31 December 2021.
| Amounts in DKKm | Revenue | EBITDA | Equity |
|---|---|---|---|
| 31 December 2021 | approx. +65 | approx. +60 | approx. +110 |
| 31 December 2020 | approx. 0 | approx. 0 | approx. +90 |
| Amounts in DKKm | Cash | Receivables | Liabilities | Other | Total |
|---|---|---|---|---|---|
| 31 December 2021 | |||||
| DKK | (9) | 54 | (957) | (19) | (897) |
| USD | 67 | 69 | (176) | (84) | 14 |
| EUR | 75 | 123 | (1,093) | (1,436) | (676) |
| GBP | 4 | 342 | (21) | - | 5 |
| SEK | 3 | 135 | - | - | 105 |
| 31 December 2020 | |||||
| DKK | 18 | 53 | (936) | (14) | (794) |
| USD | 65 | 124 | (144) | (57) | 9 |
| EUR | 150 | 88 | (1,243) | (1,398) | (748) |
| GBP | 5 | 345 | (16) | - | 9 |
| SEK | 7 | 109 | - | - | 21 |
| Amounts in DKKm | Total cash flow* | Within 1 year | From 1-5 years | After 5 years | Total |
|---|---|---|---|---|---|
| 31 December 2021 | 194 | 720 | (2,350) | - | (1,436) |
| Mortgage debt and bank loans | 466 | 472 | 245 | 134 | - |
| Trade payables | 115 | 115 | 115 | 151 | - |
| Lease liabilities | 244 | 269 | 43 | 92 | - |
| Other financial liabilities | 973 | 973 | 76 | - | - |
| Financial liabilities | 1,798 | 1,829 | 1,376 | 210 | 243 |
| 31 December 2020 | 298 | 714 | (2,410) | - | (1,398) |
| Mortgage debt and bank loans | 704 | 746 | 535 | 182 | - |
| Trade payables | 74 | 74 | 74 | 106 | - |
| Lease liabilities | 746 | 901 | 126 | - | - |
| Other financial liabilities | 239 | 270 | 38 | - | - |
| Financial liabilities | 1,918 | 1,991 | 1,042 | 661 | 288 |
* Total cash flow includes interests.
In connection with the ALK Group’s ongoing financing of operations, including refinancing, efforts are made to ensure adequate and flexible liquidity. This is guaranteed by placing free funds in credit-worthy, liquid, interest bearing instruments of relatively short durations in accordance with the ALK Group’s policy. The liquidity risk is considered to be minimal due to the ALK Group’s current capital structure.
| Amounts in DKKm | Currency | Expiry date | Carrying amount | Fixed/ floating interest rate | Effective interest rate |
|---|---|---|---|---|---|
| 31 December 2021 | |||||
| Cash | DKK | Various | 194 | Floating | (1.09)-(0.10) |
| Interest-bearing assets | 194 | ||||
| Mortgage debt | DKK | 2035 | 240 | Floating | 0.2 |
| Lease liabilities | EUR | 2022 | 244 | Fixed | 2.0 |
| Bank loans | Various | 2022-2033 | 226 | Fixed | 0.4-0.5 |
| Interest-bearing liabilities | 710 | ||||
| 31 December 2020 | |||||
| Cash | DKK | Various | 298 | Floating | (1.40)-(0.05) |
| Interest-bearing assets | 298 | ||||
| Mortgage debt | DKK | 2035 | 258 | Floating | 0.2 |
| Lease liabilities | EUR | 2022 | 239 | Fixed | 2.0 |
| Bank loans | Various | 2021-2033 | 446 | Fixed | 1.8 |
| Interest-bearing liabilities | 943 |
An increase in the interest rate of 1 percentage point on mortgage debt and bank loans would decrease net profit and equity by approximately DKK 4 million (2020: decrease of DKK 5 million). An increase in the interest of 1 percentage point on cash would increase net profit and equity by approximately DKK 2 million (2020: increase of DKK 3 million). The ALK Group does not hedge its interest rate exposure, as this is not considered to be financially viable. Concerning the ALK Group’s financial assets and financial liabilities, the earlier of the contractual revaluation and redemption date is applied. Effective interest rates are stated on the basis of the current level of interest rates on the balance sheet date.
The ALK Group’s primary credit exposure is related to trade receivables and cash. The ALK Group has no major exposure relating to one single customer or business partner. According to the ALK Group’s policy for assuming credit exposure, all customers and business partners are credit rated regularly. Trade receivables are monitored at the local level and are distributed across a number of markets and customers. Therefore, the credit risk is considered to be low. For more information, see note 3.5.
The ALK Group has made a systematic review of contracts that might contain terms that would make the contract or parts thereof a derivative financial instrument. The review did not lead to recognition of derivative financial instruments relating to the contracts.
| Amounts in DKKm | Measurement and fair value hierarchy | Revaluation/payment date | 2021 | 2020 |
|---|---|---|---|---|
| Financial assets | ||||
| 31 December 2021 | ||||
| Financial assets measured at amortised cost | ||||
| Receivables from group companies | 18 | 18 | ||
| Receivables | 226 | 263 | ||
| Trade receivables | 73 | 73 | ||
| Other receivables | 152 | 172 | ||
| Cash | 583 | 519 | ||
| Total | 1,052 | 945 | ||
| 31 December 2020 | ||||
| Financial assets measured at amortised cost | ||||
| Receivables from group companies | 18 | 18 | ||
| Receivables | 263 | 258 | ||
| Trade receivables | 73 | 73 | ||
| Other receivables | 172 | 151 | ||
| Cash | 519 | 298 | ||
| Total | 1,045 | 798 |
| Amounts in DKKm | Impairment method | 12m ECL | Lifetime ECL (simplified approach) | Total |
|---|---|---|---|---|
| Financial assets | ||||
| 31 December 2021 | ||||
| Receivables from group companies | 18 | - | 18 | |
| Receivables | 226 | - | 226 | |
| Trade receivables | 73 | - | 73 | |
| Other receivables | 152 | - | 152 | |
| Cash | 583 | - | 583 | |
| Total | 1,052 | - | 1,052 | |
| 31 December 2020 | ||||
| Receivables from group companies | 18 | - | 18 | |
| Receivables | 263 | - | 263 | |
| Trade receivables | 73 | - | 73 | |
| Other receivables | 172 | - | 172 | |
| Cash | 298 | - | 298 | |
| Total | 824 | - | 824 |
| Amounts in DKKm | Within 1 year | From 1-5 years | After 5 years | Total |
|---|---|---|---|---|
| Financial liabilities | ||||
| 31 December 2021 | ||||
| Financial liabilities measured at amortised cost | ||||
| Mortgage debt | 240 | 73 | 152 | |
| Bank loans | 226 | 12 | 29 | |
| Lease liabilities | 244 | 583 | - | |
| Trade payables | 115 | - | - | |
| Other payables | 950 | - | - | |
| Total | 1,775 | 668 | 181 | |
| 31 December 2020 | ||||
| Financial liabilities measured at amortised cost | ||||
| Mortgage debt | 258 | 73 | 446 | |
| Bank loans | 446 | 18 | - | |
| Lease liabilities | 239 | 519 | - | |
| Trade payables | 74 | - | - | |
| Other payables | 880 | - | - | |
| Total | 1,897 | 610 | 446 |
All financial assets and liabilities are measured at cost or amortised cost. The carrying amounts for these approximate fair value. Fair value for mortgage debt is measured by level 1 input (quoted prices in active markets) from the fair value hierarchy and fair value for bank loans is measured by level 2 input (inputs other than quoted markets that are observable) from the fair value hierarchy.
No financial derivatives were used in 2021 or 2020.
In 2021, the ALK Group extended its financial resources with a DKK 1,500 million credit facility which runs until the end of 2024. By the end of 2021, DKK 223 million was drawn.# Consolidated financial statements • Annual report 2021 • ALK 83
Accounting policies
Financial assets
On initial recognition, investments and other financial assets are measured at cost, corresponding to fair value. They are subsequently measured at fair value either through the income statement or through comprehensive income.
Financial liabilities
Other financial liabilities, including bank loans and trade and other payables, are on initial recognition measured at fair value. The liabilities are subsequently measured at amortised cost.
Debt
Trade payables, other payables, including sales discounts and rebates as well as debt to public authorities etc., are measured at amortised cost.
Mortgage debt
Mortgage debt is recognised on the raising of a loan at cost, equalling fair value of the proceeds received, and net of transaction costs incurred. Subsequently, mortgage debt is measured at amortised cost.
The ALK Group has established long-term equity-based incentive plans linked to the creation of shareholder value and the fulfilment of strategic goals. The plans are established for the members of Board of Management and other key employees, reward long-term value creation and align to interests of the shareholders.
The plan was conditional upon strategic key performance indicators being attained. Based on the financial results for 2020, the KPI achievements exceeded their targets increasing the granted number of performance shares and share options by 100%. However, the overall payout of the plan on the vesting date for the performance shares and on the exercise date for the share options can never exceed a total value of 300% of the recipient’s 2018 annual base salary. The incentive plans consist of share options and performance share units that are considered sufficiently covered by treasury shares.
Expensed in the income statement:
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| Ordinary incentive plans | ||
| Cost of sales | 5 | 1 |
| Research and development expenses | 7 | 3 |
| Sales and marketing expenses | 11 | 6 |
| Administrative expenses | 12 | 9 |
| Total | 36 | 29 |
The share options entitle the holder to acquire one existing B share of DKK 10 nominal value in the company per share option and the performance share units entitle the holder to receive one existing B share per performance share unit free of charge. Cost for the year regarding share-based payments is recognised as follows:
In 2021, the total cost of share-based payments included a financial expense of DKK 1 million due to the exercise and cash settlement of share options (2020: DKK 1 million). The total cost included DKK 11 million related to adjustment in the share options and performance share units expected to vest (2020: DKK 5 million).
The vesting period for both share options and performance share units is three years after grant. Vesting is conditional upon certain targets being met and upon the participant not having resigned. Target achievement is met upon fulfilment of strategic key performance indicators. In case performance is below the threshold there will be no units vesting, and if above target, a multiplier is applied that can increase the vesting by up to 100%.
The exercise of share options is possible in the trading windows following the release of annual and interim reports conditional upon the share option holder not having resigned at the time of exercise. For performance share units, the final transfer of ownership takes place at vesting three years after the grant.
Special incentive plan 2018
ALK’s special incentive plan was a one-time scheme designed to implement ALK’s growth strategy and consisted of both share options and performance share units with a vesting period of three years. The special incentive plan was adopted at the annual general meeting in March 2018 and vested in March 2021. The grant value of the plan did not exceed 50% of the Executive’s 2018 annual base salary on the grant date.
Specification of outstanding share options and performance share units:
| Board of Management units | Other key employees units | Board of Management units | Other key employees units | Total units | Total units | |
|---|---|---|---|---|---|---|
| Share options | Share options | Performance share units | Performance share units | 2021 | 2020 | |
| Outstanding at 1 January | 89,758 | 59,338 | 149,096 | 972 | 13,444 | 13,569 |
| Additions | 29,811 | 25,494 | 55,305 | 1,129 | 6,250 | 3,024 |
| Exercised/settled | (55,279) | (46,323) | (101,602) | (13,183) | (13,183) | (3,149) |
| Expired | 0 | (100) | (100) | 0 | 0 | (585) |
| Outstanding at 31 December | 64,290 | 38,409 | 102,699 | 35,426 | 32,420 | 15,552 |
| Total number of vested share options | 49,247 | |||||
| Average remaining life at year end (years) | 2.1 | |||||
| Exercise prices at year end (DKK) | 802-2,320 |
| Board of Management units | Other key employees units | Board of Management units | Other key employees units | Total units | Total units | |
|---|---|---|---|---|---|---|
| Share options | Share options | Performance share units | Performance share units | 2021 | 2020 | |
| Outstanding at 1 January | 98,263 | 62,293 | 160,556 | 904 | 13,444 | 13,569 |
| Additions | 13,253 | 12,130 | 25,383 | 1,332 | 3,024 | 3,024 |
| Exercised/settled | (21,758) | (15,085) | (36,843) | (954) | (12,774) | (12,774) |
| Cancellations | - | - | - | - | (585) | (585) |
| Outstanding at 31 December | 89,758 | 59,338 | 149,096 | 972 | 35,426 | 15,552 |
| Total number of vested share options | 32,467 | |||||
| Average remaining life at year end (years) | 2.6 | |||||
| Exercise prices at year end (DKK) | 783-1,372 |
The Board of Directors decided for one trading window in 2021 to settle share options by cash and a total of 66,986 share options were exercised and total cash payments amounted to DKK 62 million. For three trading windows the Board of Directors decided to settle share options by shares and a total of 34,616 share options were exercised.
The Board of Directors decided for two trading windows in 2020 to settle share options by cash and a total of 24,945 share options were exercised and total cash payments amounted to DKK 24 million. For two trading windows the Board of Directors decided to settle share options by shares and a total of 11,898 share options were exercised.
Outstanding share options and performance share units have the following characteristics:
| Share options | Share options | Performance share units | Performance share units | |
|---|---|---|---|---|
| 2021 Plan | 2020 Plan | 2021 Plan | 2020 Plan | |
| Units | 102,699 | 32,420 | ||
| Fair value at grant date is measured in accordance with the Black & Scholes model for valuation of share options, using the following assumptions: | ||||
| Average exercise price (DKK) | 2,320 | 1,372 | ||
| Exercise period (years) | 2,498 | 1,477 | ||
| Expected volatility rate, based on the historical volatility | 36% p.a. | 34% p.a. | ||
| Expected option life | 4 years | 4 years | ||
| Expected dividend per share | - | - | ||
| Risk-free interest rate | -0.49% p.a. | -0.01% p.a. | ||
| Calculated fair value of granted share options (DKK) | 576 | 328 |
Fair value of share options and performance share units granted:
| Plan | 2018 Plan – special plan* | 2019 Plan | 2020 Plan | 2021 Plan |
|---|---|---|---|---|
| Units | 39,798 | 23,738 | 18,677 | 11,037 |
| Average share price (DKK) | 1,113 | 802 | 1,141 | 1,460 |
| Expected exercise price (DKK) | 3,660 | 5,789 | 802 | 1,141 |
| Vested as per 1 Mar 2019 | 13,241 | |||
| Vested as per 1 Mar 2021 | 11,314 | |||
| Vested as per 1 Mar 2022 | 7,865 | |||
| Vested as per 1 Mar 2023 | 4,535 | |||
| Vested as per 1 Mar 2024 | 3,401 |
Accounting policies
Share-based incentive plans (equity-settled share-based payments), which comprise share options and performance share units, are measured at the grant date at fair value and recognised in the income statement under the respective functions over the vesting period and offset in equity. The fair value of share options is determined using the Black & Scholes model. The exercise price is equivalent to the average market price of the share for the five trading days immediately preceeding the date of grant and is increased by 2.5% p.a. and reduced by dividends paid. The fair value of performance share units is determined using the average share price (closing) five days after annual general meeting.
The ALK Group settles the equity-settled share-based incentive plans in shares. However, the share option agreement entitles the ALK Group to demand cash settlement of the options. The ALK Group recognises share options, in case of cash settlement, as other liabilities and adjusts to fair value as from the time when the ALK Group has an obligation to settle in cash. The ALK Group recognises subsequent adjustment to fair value in the income statement under financial income or financial expenses.
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| Cash | 194 | 298 |
| Undrawn facilities | 1,277 | 600 |
| Total | 1,471 | 898 |
Adjustment for non-cash items
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| Tax on profit | 60 | 13 |
| Financial income and expenses | 36 | 76 |
| Share-based payments | 49 | 29 |
| Depreciation, amortisation and impairment | 242 | 245 |
| Other adjustments* | 49 | 63 |
| Total | 400 | 462 |
In 2021 the ALK Group extended its financial resources with a DKK 1,500 million credit facility which runs until the end of 2024. By the end of 2021, DKK 223 million was drawn.
* Other adjustments include non-cash transactions related to the divestment of ALK’s part-share of a formulation production line for tablets to production partner Catalent of DKK 33 million (2020: DKK 37 million). In 2020, other adjustments further included provision for transition period for the Danish Holiday Act of DKK 39 million.
Financial reserves
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
The cash flow statement of the ALK Group is presented using the indirect method and shows cash flows from operating, investing and financing activities as well as cash at the beginning and at the end of the financial year.
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| Change in inventories | (84) | (69) |
| Change in receivables and prepayments | (5) | (159) |
| Change in short-term payables | 61 | 74 |
| Total | (28) | (154) |
The cash effect of acquisitions and divestments is shown separately under cash flows from investing activities. In the cash flow statement, cash flows concerning acquired companies are recognised from the date of acquisition, while cash flows concerning divested companies are recognised until the date of divestment.
Cash flows from operating activities are stated as net profit, adjusted for non-cash operating items and changes in working capital, less the income tax paid and plus net financial items.
| Reconciliation of liabilities arising from financing activities | Amounts in DKKm | 2021 | 2020 |
|---|---|---|---|
| Liabilities from financing activities at 1 January | 943 | 990 | |
| Proceeds from borrowings | 226 | - | |
| Repayment of borrowings | (464) | (19) | |
| New leases | 34 | 11 | |
| Installments of lease liabilities | (32) | (30) | |
| Exchange rate adjustments | 3 | (9) | |
| Total | 710 | 943 |
Cash flows from investing activities comprise payments in connection with acquisition and divestment of companies and financial assets as well as purchase, development, improvement and sale of intangible and tangible assets.
Cash flows from financing activities comprise changes to the parent company’s share capital and related costs as well as the raising and repayment of loans, instalments on interest-bearing debt, lease liabilities, purchase of treasury shares, and settlement of share options and payment of dividends.
Consolidated financial statements • Annual report 2021 • ALK 88
ALK-Abelló A/S is controlled by the Lundbeck Foundation (Lundbeckfond Invest A/S) domiciled in Copenhagen, Denmark, which holds 67.2% of the total number of votes in ALK Abelló A/S. The remaining shares are widely held. ALK-Abelló A/S is parent company, and ultimate parent for the ALK Group is the Lundbeck Foundation (Lundbeckfond Invest A/S, incorporated in Denmark).
Other related parties comprise ALK’s Board of Management and Board of Directors, companies in which the majority shareholder exercises control, and such companies’ subsidiaries, in this case H. Lundbeck A/S and Falck A/S and their subsidiaries.
Transactions and balances with the parent company’s majority shareholder:
Transactions with key management personnel consist of remuneration and exercise of share options, see notes 2.4 and 5.1 of the consolidated financial statements. No other transactions have taken place during the year with Board of Directors, Board of Management, major shareholders or other related parties.
Consolidated financial statements • Annual report 2021 • ALK 89
No events have occurred after the reporting period, that influence the evaluation of the consolidated financial statements.
The financial statements were approved by the Board of Directors and authorised for issue on 8 February 2022.
Cash comprise cash subject to an insignificant risk of changes in value less any overdraft facilities that are an integral part of the ALK Group’s cash management.
Cash flows in currencies other than the functional currency are recognised in the cash flow statement using average exchange rates for the individual months if these are a reasonable approximation of the actual exchange rates at the transaction dates. If this is not the case, the actual exchange rates for the specific days in question are used.
| Entity | Country | Percentage of shares owned | Activity |
|---|---|---|---|
| Parent company | |||
| ALK-Abelló A/S | Denmark | 100% | Activity Parent company |
| Subsidiaries by geographical area | |||
| Europe | |||
| ALK-Abelló Allergie-Service GmbH | Germany | 100% | Production |
| ALK-Abelló Nordic A/S | Denmark | 100% | Sales & Distribution |
| ALK-Abelló Nordic A/S (branch) | Finland | 100% | Sales & Distribution |
| ALK-Abelló Nordic A/S (branch) | Norway | 100% | Sales & Distribution |
| ALK-Abelló Nordic A/S (branch) | Sweden | 100% | Sales & Distribution |
| ALK e-com A/S | Denmark | 100% | Sales & Distribution |
| ALK S.A.S. | France | 100% | Sales & Distribution |
| ALK-Abelló Arzneimittel GmbH | Germany | 100% | Sales & Distribution |
| ALK-Abelló B.V.* | Netherlands | 100% | Sales & Distribution |
| ALK-Abelló Sp. z o.o. | Poland | 100% | Sales & Distribution |
| ALK Slovakia s.r.o. | Slovakia | 100% | Sales & Distribution |
| ALK Slovakia s.r.o. – od šteˇpny´ zavod (branch) | Czech Republic | 100% | Sales & Distribution |
| ALK-Abelló S.A. | Spain | 100% | Sales & Distribution |
| ALK-Abelló S.p.A. | Italy | 100% | Sales & Distribution |
| ALK AG (In liquidation) | Switzerland | 100% | Services |
| ALK-Abelló AG | Switzerland | 100% | Sales & Distribution |
| ALK-Abelló Ltd. | United Kingdom | 100% | Sales & Distribution |
| North America | |||
| ALK-Abelló Pharmaceuticals, Inc. | Canada | 100% | Research & Development |
| ALK-Abelló, Inc. | USA | 100% | Sales & Distribution |
| OKC Allergy Supplies Inc. | USA | 100% | Sales & Distribution |
| ALK-Abelló, Source Materials, Inc. | USA | 100% | Production |
| OKC Crystal Laboratory Inc. | USA | 100% | Research & Development |
| International markets | |||
| ALK-Abelló A/S (branch) | China | 100% | Sales & Distribution |
| ALK (Shanghai) Medical Technology Company Limited (Dormant) | China | 100% | Research & Development |
| ALK ilaç ve Alerji Ürünleri Ticaret | Turkey | 100% | Sales & Distribution |
Consolidated financial statements • Annual report 2021 • ALK 90
| Term | Definitions | Amounts in DKKm | 2021 | 2020 |
|---|---|---|---|---|
| Alternative Performance Measures | ||||
| Gross margin – % | Gross profit x 100 / Revenue | |||
| EBITDA margin – % | EBITDA x 100 / Revenue | |||
| Net asset value per share | Net asset value / Number of shares end of period | |||
| Invested capital | Intangible assets, tangible assets, inventories and current receivables reduced by liabilities except for mortgage debt and bank loans | |||
| EBITDA reconciliation to net profit | Net profit | |||
| Tax on profit/(loss) | 219 | 76 | ||
| Financial income | 60 | (5) | ||
| Financial expenses | (10) | 54 | ||
| Depreciation, amortisation and impairment | 23 | 25 | ||
| EBITDA | 242 | 245 | ||
| Return on equity (ROE) – % | Net profit/(loss) for the period x 100 / Average equity | |||
| Net asset value | Equity | 3,480 | 3,153 | |
| Pay-out ratio – % | Proposed dividend x 100 / Net profit/(loss) for the year | |||
| Net asset value | 3,480 | 3,153 | ||
| Earnings/(loss) per share (EPS) | Net profit/(loss) for the period / Average number of outstanding shares | |||
| Intangible assets | 534 | 395 | ||
| Tangible assets | 622 | 583 | ||
| Inventories | 1,814 | 1,704 | ||
| Trade receivables | 1,204 | 1,093 | ||
| Receivables from group companies | 583 | 544 | ||
| Income tax receivables | 20 | - | ||
| Other receivables | 12 | 14 | ||
| Prepayments | 82 | 96 | ||
| Invested capital | 2,931 | 2,807 | ||
| Earnings/(loss) per share diluted (DEPS) | Net profit/(loss) for the period / Average number of outstanding shares diluted | |||
| Cash flow per share (CFPS) | Cash flow from operating activities / Average number of outstanding shares | |||
| ROIC incl. goodwill – % | Operating profit x 100 / Average invested capital incl. goodwill | |||
| Price earnings ratio (PE) | Share price / Earnings per share | |||
| Markets | Geographical markets (based on customer location): • Europe comprises the EU, UK, Norway and Switzerland • North America comprises the USA and Canada • International markets comprise Japan, China and all other countries | |||
| Pensions and similar liabilities | (345) | (207) | ||
| Lease liabilities (non-current) | (207) | (115) | ||
| Deferred income (non-current) | (42) | (37) | ||
| Trade payables | (4) | (12) | ||
| Lease liabilities (current) | (23) | (950) | ||
| Deferred income (current) | (324) | (207) | ||
| Provisions (current) | (42) | (115) | ||
| Income tax payables (current) | (37) | (4) | ||
| Other payables | (12) | (23) |
The definitions are aligned with generally accepted financial ratios applied by financial analysts. The definitions are part of the Management’s review.
Consolidated financial statements • Annual report 2021 • ALK 91
Parent company financial statements • Annual report 2021 • ALK 91
| Accounting policies | 1 | 95 | 12 |
| Revenue and segment information | 2 | 96 | 13 |
| Staff costs | 3 | 97 | 14 |
| Financial income and expenses | 5 | 97 | 15 |
| Intangible assets | 7 | 98 | 16 |
| Property, plant and equipment | 8 | 98 | 17 |
| Deferred tax | 9 | 99 | 18 |
| Investments in subsidiaries | 10 | 100 | 19 |
| Inventories | 11 | 100 | |
| Mortgage debt and bank loans | 12 | 100 | |
| Pensions and similar liabilities | 13 | 101 | |
| Lease liabilities | 14 | 101 | |
| Income tax payables to group companies | 15 | 101 | |
| Special items | 16 | 101 | |
| Income taxes | 17 | 101 | |
| Contingent liabilities and commitments | 18 | 102 | |
| Fees to ALK-Abelló A/S’ auditors | 19 | 102 | |
| Proposed appropriation of net profit | 20 | 102 | |
| Events after the reporting period | 21 | 102 |
Parent company financial statements • Annual report 2021 • ALK 92
| Amounts in DKKm | Note | 2021 | 2020 |
|---|---|---|---|
| Revenue | 2 | 3,407 | 2,296 |
| Cost of sales | 3,4 | 1,029 | 1,011 |
| Gross profit | 2,378 | 1,285 | |
| Research and development expenses | 3,4 | 577 | 508 |
| Sales and marketing expenses | 3,4 | 248 | 195 |
| Administrative expenses | 3,18 | 113 | 101 |
| Other operating items, net | (2) | - | |
| Operating profit (EBIT) | 1,438 | 481 | |
| Income from investments in subsidiaries | 10 | 831 | 14 |
| Financial income | 5 | 22 | 23 |
| Financial expenses | 5 | (8) | (3) |
| Profit before tax (EBT) | 2,253 | 489 | |
| Tax on profit/(loss) | 6 | 30 | 105 |
| Net profit | 2,223 | 384 |
Parent company financial statements • Annual report 2021 • ALK 93
| 31 Dec. 2021 | 31 Dec. 2020 |
|---|---|
| 31 Dec. 2021 | 31 Dec. 2020 |
| :---------- | :---------- |# Parent company financial statements • Annual report 2021 • ALK 94
| Amounts in DKKm | Share capital | Reserve for capitalised development costs | Retained earnings | Proposed dividend | Total equity |
|---|---|---|---|---|---|
| 2021 | |||||
| Equity at 1 January | 111 | 2,771 | 313 | 36 | 3,286 |
| Appropriated from net profit | 313 | 313 | |||
| Share-based payments | 36 | 36 | |||
| Share options settled | (72) | (72) | |||
| Sale of treasury shares | 31 | 31 | |||
| Transfer to/(from) legal reserves | (1) | (1) | |||
| Tax related to items recognised directly in equity | 10 | 10 | |||
| Other transactions | 319 | (1) | 318 | ||
| Equity at 31 December | 111 | 3,090 | 3 | - | 3,204 |
See note 4.1 in the consolidated financial statements for information on treasury shares.
The financial statements of the parent company ALK-Abelló A/S for the period 1 January to 31 December 2021 have been prepared in accordance with the Danish Financial Statements Act for large reporting class D enterprises. The accounting policies are unchanged from last year.
The parent company’s accounting policies for recognition and measurement are in accordance with the ALK Group’s accounting policies with the following exceptions:
Goodwill is measured at cost less accumulated amortisation and impairment. Amortisation is calculated using the straight-line method over the expected useful life, estimated at 10 years. This estimate was made on the basis of estimated useful lives of the assets acquired.
A reserve for capitalisation of development costs less deferred tax is recognised in the statement of equity. The reserve contains development costs, less amortisation/impairment losses, and less deferred tax, capitalised since 1 January 2016.
Investments in subsidiaries are measured at cost.
Dividends from investments in subsidiaries are recognised in the parent company’s financial statements when the right to the dividend finally vests, typically at the date of the company’s approval in general meeting of the dividend of the company in question less any write-downs at the investments. Where the recoverable amount of the investments is lower than cost, the investments are written down to this lower value. In addition, cost is written down to the extent that dividends distributed exceed the accumulated earnings in the company since the acquisition date. In the event of indications of impairment, an impairment test is performed of investments in subsidiaries.
Acquisition of activities from subsidiaries is accounted for using the purchase method. On initial recognition, goodwill is measured and recognised as the excess of the consideration transferred exceeding the fair value of the net assets acquired at the acquisition date.
As allowed under section 86 (4) of the Danish Financial Statements Act, no cash flow statement is presented, as this is included in the consolidated cash flow statement.
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| Sale of goods | 2,215 | 1,953 |
| Royalties | 58 | 57 |
| Services | 654 | 609 |
| Total revenue | 2,296 | 2,015 |
| Europe | 1,969 | 1,735 |
| International markets | 327 | 280 |
| Total revenue | 2,296 | 2,015 |
Revenue is allocated as follows:
* Cost of sales: 295 (2020: 219)
* Research and development expenses: 300 (2020: 198)
* Sales and marketing expenses: 96 (2020: 77)
* Administrative expenses: 45 (2020: 44)
* Included in the cost of assets: 45 (2020: 44)
* Total: 749 (2020: 708)
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| Wages and salaries | 654 | 59 |
| Pensions | 12 | 22 |
| Other social security costs, etc. | 81 | 81 |
| Share-based payments | 4 | 24 |
| Total | 749 | 708 |
Remuneration to Board of Management and Board of Directors: See note 2.4 and 5.1 in the consolidated financial statements.
| Employees | Average number (FTE) | Number year end (FTE) |
|---|---|---|
| 913 | 855 | |
| 954 | 873 |
Special items include impairment of assets of DKK 9 million (2020: DKK 24 million) of which DKK 2 million is related to intangible assets (2020: DKK 22 million) and DKK 7 million is related to tangible assets (2020: DKK 2 million). Further, special items include impairment of investments in subsidiaries of DKK 4 million (2020: DKK 0).
The impairment of intangible assets of DKK 2 million is related to impairment of software. In the income statement, the impairment of intangible assets is recognised as sales and marketing expenses. The impairment of tangible assets of DKK 7 million is related to impairment of plant and machinery. In the income statement, the impairment of tangible assets is recognised with DKK 6 million as cost of sales and DKK 1 million as research and development expenses. The impairment of investments in subsidiaries includes DKK 4 million impairment of ALK Abelló A/S’ investment in its subsidiary in Turkey.
In 2020, the impairment of intangible assets included DKK 13 million relating to impairment of acquired intellectual property rights and DKK 9 million relating to impairment of software projects in progress. In the income statement, the impairment of intangible assets was recognised with DKK 19 million in research and development expenses and DKK 3 million as cost of sales. The impairment of tangible assets included DKK 2 million related to impairment of production equipment in progress. In the income statement, the impairment of tangible assets was recognised as cost of sales.
For the assets where ALK estimates that there is a recoverable amount, such amount was determined based on the fair value less cost to sell or the value in use of the respective asset.
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| Interest on receivables from group companies | 12 | 10 |
| Other interest income | 4 | 4 |
| Currency gain, net | 6 | - |
| Total financial income | 22 | 14 |
| Other interest expenses* | 23 | 29 |
| Currency loss, net | - | 20 |
| Total financial expenses | 23 | 49 |
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| Current income tax | (11) | 28 |
| Adjustment of deferred tax | 41 | 79 |
| Prior year adjustments, income tax | 3 | (2) |
| Prior year adjustments, deferred tax | 79 | - |
| Total | 104 | 105 |
| Profit before tax | 343 | 994 |
|---|---|---|
| Income tax, tax rate of 22% | 75 | 219 |
| Non-taxable income | (22) | (199) |
| Non-deductible expenses | 9 | 9 |
| Prior year adjustments, income tax | 3 | (2) |
| Prior year adjustments, deferred tax | (3) | - |
| Other taxes and adjustments | (32) | 78 |
| Tax on profit for the year | 30 | 105 |
| Amounts in DKKm | Goodwill and rights | Patents, trademarks | Development cost* | Software | Assets in progress | Other | Total |
|---|---|---|---|---|---|---|---|
| Cost | |||||||
| Beginning of year | 867 | 14 | 280 | 40 | 1,270 | 1,267 | 3,738 |
| Additions | 69 | 9 | 7 | 27 | 43 | 25 | 183 |
| Disposals | - | - | (2) | (9) | (11) | (22) | (44) |
| Transfer to/from other groups | - | - | - | - | - | - | - |
| Cost year end | 867 | 23 | 287 | 58 | 1,302 | 1,270 | 3,877 |
| Amortisation and impairment | |||||||
| Beginning of year | 867 | 7 | 210 | 287 | 1,151 | 1,130 | 3,652 |
| Amortisation for the year | 67 | 1 | 21 | 24 | 287 | 263 | 923 |
| Amortisation on disposals | - | - | - | - | (1) | (18) | (19) |
| Impairment for the year | - | - | - | - | - | - | - |
| Amortisation and impairment year end | 867 | 8 | 231 | 311 | 1,437 | 1,275 | 4,556 |
| Carrying amount year end | 0 | 15 | 56 | (53) | (135) | (5) | (679) |
| of which assets held under leases* | - | - | - | - | - | - | - |
| Amounts in DKKm | Land and buildings | Plant and machinery | Fixtures and equipment | Property, plant and equipment in progress | Other | Total |
|---|---|---|---|---|---|---|
| Cost | ||||||
| Beginning of year | 611 | 526 | 42 | 236 | 1,415 | 2,830 |
| Additions | 11 | 12 | 9 | 71 | 103 | 206 |
| Disposals | (1) | (18) | - | - | (19) | (38) |
| Transfer to/from other groups | - | - | - | 23 | (28) | (5) |
| Cost year end | 622 | 536 | 51 | 279 | 1,371 | 3,203 |
| Depreciation and impairment | ||||||
| Beginning of year | 642 | 614 | 2 | 85 | 642 | 1,985 |
| Depreciation for the year | 72 | 57 | 2 | 40 | 702 | 1,573 |
| Depreciation of disposals | (19) | (31) | - | - | (19) | (69) |
| Impairment for the year | - | - | - | (2) | (2) | (4) |
| Depreciation and impairment year end | 702 | 640 | 4 | 123 | 1,323 | 3,485 |
| Carrying amount year end | (80) | (104) | 47 | 156 | 48 | (282) |
| of which assets held under leases* | 186 | - | - | - | - | 186 |
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| Intangible assets | 312 | 111 |
| Tangible assets | 194 | 127 |
| Total equity | 3,204 | 2,886 |
| The development projects are generating economic benefits in the form of sale of goods. At 31 December 2021, the capitalized development cost relates to the historical development of the adrenaline auto-injector Jext® for the European market. Additions of DKK 9 million relate to development projects in progress. |
| Amounts in DKKm | Total | 2021 Carrying amount beginning of year | Adjustment to prior years | Recognised in the income statement, net | Recognised in equity, net (share-based payments) | Carrying amount year end |
|---|---|---|---|---|---|---|
| Intangible assets | (3) | (65) | 60 | - | (13) | |
| Tangible assets | (23) | 30 | - | 10 | (23) | |
| Current and other assets | 304 | - | (22) | 33 | 326 | |
| Tax losses carried forward | 3 | (41) | 10 | 3 | (17) | |
| Total | 277 | (76) | 48 | 46 | 299 | |
| 2020 Carrying amount beginning of year | Adjustment of receivables from group companies | Recognised in the income statement, net | Recognised in equity, net (share-based payments) | Carrying amount year end | ||
| Intangible assets | 16 | (59) | 17 | - | 8 | |
| Tangible assets | 31 | - | (1) | 35 | 65 | |
| Current and other assets | 351 | 6 | (61) | 8 | 304 | |
| Tax losses carried forward | 6 | (79) | 43 | - | (30) | |
| Total | 404 | (132) | 0 | 43 | 347 |
ALK-Abelló A/S is included in a joint Danish taxation scheme with the Lundbeck Foundation (Lundbeckfond Invest A/S) and its Danish subsidiaries. ALK-Abelló A/S recognises deferred tax assets including the tax value of tax losses if it is probable that it can be utilised against future taxable income within a foreseeable future. This includes an assessment of the possibilities to utilise tax losses in the joint Danish taxation scheme with the Lundbeck Foundation (Lundbeckfond Invest A/S).
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| Cost beginning of year | 1,470 | 1,466 |
| Capital contribution in subsidiaries during the year | - | 4 |
| Cost year end | 1,470 | 1,470 |
| Write-down beginning of year | 408 | 408 |
| Write-down during the year, cf. note 4 | 4 | - |
| Write-down year end | 412 | 408 |
| Carrying amount year end | 1,058 | 1,062 |
In the income statement, income from investments in subsidiaries amounting to DKK 15 million (2020: DKK 831 million) is net amount of DKK 19 million dividends received (2020: DKK 831 million) and DKK 4 million write-down of investments in subsidiaries (2020: DKK 0).
For an overview of all subsidiaries see note 5.6 in the consolidated financial statements.
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| Raw materials | 102 | 34 |
| Work in progress | 284 | 75 |
| Manufactured goods and goods for resale | 34 | 255 |
| Total | 420 | 361 |
Amount of write-down of inventories during the year | 13 | 4 |
Amount of reversal of write-down of inventories during the year | 8 | 2 |
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| Debt to mortgage credit institutions secured by real property | ||
| Mortgage debt is due as follows: | ||
| Within 1 year | 18 | 73 |
| From 1-5 years | 149 | 168 |
| After 5 years | 73 | 17 |
| Total | 240 | 258 |
| Bank loans | ||
| Bank loans are due as follows: | ||
| Within 1 year | 223 | 446 |
| From 1-5 years | - | - |
| After 5 years | - | - |
| Total | 223 | 446 |
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| Within 1 year | - | 1 |
| From 1-5 years | 3 | 2 |
| After 5 years | 55 | 55 |
| Total | 58 | 58 |
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| Within 1 year | 10 | 79 |
| From 1-5 years | 41 | 8 |
| After 5 years | 79 | 35 |
| Total | 130 | 129 |
Non-current income tax payables to group companies of DKK 115 million (2020: DKK 111 million) is expected to expire between 1 to 5 years.
In December 2021, ALK-Abelló A/S issued a hold-harmless letter to ALK -Abelló Arzneimittel GmbH regarding costs under the ongoing tax audits in Germany (unlimited guarantee). The hold-harmless letter replaces the letter issued in December 2020.
In January 2022, ALK-Abelló A/S issued a letter of financial support to ALK e-com A/S. The Letter affirms Financial support for ALK e-com A/S for a period of at least 12 months from the date of approval of the 31 December 2021 financial statements.
ALK-Abelló A/S is included in the consolidated financial statements of the Lundbeck Foundation (Lundbeckfond Invest A/S, incorporated in Denmark).
ALK-Abelló A/S has had transactions with subsidiaries during 2021. All subsidiaries are owned 100%. The transactions are eliminated in the consolidated financial statements. Transactions with the majority shareholder are disclosed in note 5.3 in the consolidated financial statements.
Apart from remuneration, no other transactions have taken place during the year with Board of Directors, Board of Management, major shareholders or other related parties.
Remuneration etc. to Board of Directors and Board of Management
For information on remuneration and exercise of share options for the ALK Group’s Board of Directors and Board of Management, see note 2.4 and 5.1 in the consolidated financial statements.
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| Fees to the auditors appointed at the annual general meeting: | ||
| Audit services | - | 2 |
| Tax advisory services | - | 1 |
| Other services | - | 2 |
| Total | 3 | 5 |
| Amounts in DKKm | 2021 | 2020 |
|---|---|---|
| Proposed dividend | 313 | 889 |
| Retained earnings | - | - |
| Net profit | 313 | 889 |
| Total | 313 | 889 |
No events have occurred after the reporting period, that influence the evaluation of the parent company financial statements.
| Amounts in DKKm | Q4 2021 unaudited | Q3 2021 unaudited | Q2 2021 unaudited | Q1 2021 unaudited | Q4 2020 unaudited | Q3 2020 unaudited | Q2 2020 unaudited | Q1 2020 unaudited |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 3,916 | 2,931 | 3,480 | 5,830 | 5,718 | 2,908 | 3,314 | 5,575 |
| Cost of sales | 1,520 | 1,234 | 240 | 1,099 | 398 | 179 | 372 | 71 |
| Research and development expenses | 292 | (13) | 279 | 219 | 294 | 147 | 291 | 52 |
| Sales and marketing expenses | (13) | (23) | 30 | 304 | 30 | 30 | 304 | 30 |
| Administrative expenses | (22) | 33 | 326 | 3 | (41) | 10 | 3 | (17) |
| Other operating items, net | 3 | (41) | 10 | 3 | (17) | - | - | 1 |
| Operating profit (EBIT) | (17) | (64) | 24 | 40 | 315 | 298 | - | - |
| Net financial items | - | - | - | - | - | - | - | - |
| Profit before tax (EBT) | - | - | - | - | - | - | - | - |
| Net profit | - | - | - | - | - | - | - | - |
| Cash flow and investments | ||||||||
| Depreciation, amortisation and impairment | 79 | 57 | 158 | (105) | (23) | (82) | 53 | 69 |
| Cash flow from operating activities | (5) | 74 | 76 | - | 242 | 468 | (266) | (45) |
| Cash flow from investing activities | (266) | (218) | 202 | 57 | 158 | (105) | (23) | (82) |
| – of which investment in intangible assets | (45) | (23) | (82) | 53 | 69 | 99 | (78) | (11) |
| – of which investment in tangible assets | (218) | (202) | 53 | 42 | 60 | 127 | (41) | (7) |
| Free cash flow | 202 | 53 | 42 | 86 | 166 | 6 | 172 | 127 |
| EBITDA | 136 | 124 | 226 | 127 | 223 | 127 | 226 | 127 |
| Average number of employees (FTE) | 2,492 | 2,525 | 2,502 | 2,481 | 2,459 | 2,492 | 2,525 | 2,502 |
| Amounts in DKKm | 2021 unaudited | 2021 unaudited | 2021 unaudited | 2021 unaudited | 2020 unaudited | 2020 unaudited | 2020 unaudited | 2020 unaudited |
|---|---|---|---|---|---|---|---|---|
| Q4 | Q3 | Q2 | Q1 | Q4 | Q3 | Q2 | Q1 | |
| Balance sheet | ||||||||
| Total assets | 5,830 | 2,931 | 3,480 | 5,830 | 5,718 | 2,908 | 3,314 | 5,575 |
| Invested capital | 2,931 | 3,480 | 5,830 | 5,718 | 2,908 | 3,314 | 5,575 | 2,803 |
| Equity | 3,480 | 5,830 | 5,718 | 2,908 | 3,314 | 5,575 | 2,803 | 3,249 |
| 2021 | 2021 | 2021 | 2021 | 2020 | 2020 | 2020 | 2020 | |
|---|---|---|---|---|---|---|---|---|
| Q4 | Q3 | Q2 | Q1 | Q4 | Q3 | Q2 | Q1 | |
| Dividend | - | - | - | - | - | - | - | - |
| Share capital | 111 | 111 | 111 | 111 | 111 | 111 | 111 | 111 |
| Shares in thousands | 11,141 | 11,141 | 11,141 | 11,141 | 11,141 | 11,141 | 11,141 | 11,141 |
| of DKK 10 each | ||||||||
| Share price, end period – DKK | 3,430 | 312 | 2,698 | 297 | 2,992 | 292 | 2,410 | 298 |
| Net asset value per share – DKK | 312 | - | - | - | - | - | - | - |
| Europe | North America | International markets | Total revenue | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | % | 2020 | % | 2021 | % | 2020 | % | 2021 | % | 2020 | % | 2021 | % | 2020 | % | |
| SCIT/SLIT-drops | 1,273 | (4) | 1,340 | (4) | 302 | (14) | 366 | (11) | 80 | (1) | 31 | (153) | 1,655 | (1) | 1,774 | (29) |
| SLIT-tablets | 1,340 | (31) | 196 | (8) | 120 | (42) | 261 | (27) | 314 | (18) | 76 | (11) | 928 | (20) | 388 | (5) |
| Other products and services | 795 | (7) | 366 | (7) | 193 | (20) | 86 | (11) | 111 | (6) | 31 | (153) | 487 | (10) | 483 | (0) |
| Total | 3,408 | (17) | 1,899 | (6) | 615 | (21) | 713 | (18) | 505 | (12) | 138 | (30) | 4,470 | (10) | 2,274 | (22) |
| Europe | North America | International markets | Total revenue | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | % | 2020 | % | 2021 | % | 2020 | % | 2021 | % | 2020 | % | 2021 | % | 2020 | % | |
| SCIT/SLIT-drops | 1,273 | (4) | 1,340 | (4) | 302 | (14) | 366 | (11) | 80 | (1) | 31 | (153) | 1,655 | (1) | 1,774 | (29) |
| SLIT-tablets | 1,340 | (31) | 196 | (8) | 120 | (42) | 261 | (27) | 314 | (18) | 76 | (11) | 928 | (20) | 388 | (5) |
| Other products and services | 795 | (7) | 366 | (7) | 193 | (20) | 86 | (11) | 111 | (6) | 31 | (153) | 487 | (10) | 483 | (0) |
| Total | 3,408 | (17) | 1,899 | (6) | 615 | (21) | 713 | (18) | 505 | (12) | 138 | (30) | 4,470 | (10) | 2,274 | (22) |
| Key figures | ||||||||||||||||
| Gross margin – % | 683 | 14 | 20.0 | 19.8 | 42.7 | 11.0 | 64 | 12 | 6.9 | 6.9 | 14.4 | 11.0 | 60 | 13 | 3.4 | 3.4 |
| EBITDA margin – % | 11.6 | 11.5 | 11.6 | 8.1 | – | – | – | – | – | – | – | – | – | – | – | – |
| Earnings per share (EPS) – DKK | 11.6 | 8.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Earnings per share diluted (DEPS) – DKK | ||||||||||||||||
| Cash flow per share (CFPS)– DKK | 10.3 | |||||||||||||||
| Share price/Net asset value |
| Europe | North America | International markets | Total revenue | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | % | 2020 | % | 2021 | % | 2020 | % | 2021 | % | 2020 | % | 2021 | % | 2020 | % | |
| SCIT/SLIT-drops | 2,809 | (10) | 1,099 | (9) | 795 | (7) | 366 | (-7) | 111 | (6) | 31 | (153) | 3,715 | (6) | 1,774 | (29) |
| SLIT-tablets | 1,273 | (-4) | 1,340 | (31) | 366 | (-7) | 400 | (31) | 31 | (15) | 76 | (11) | 1,670 | (17) | 388 | (5) |
| Other products and services | 196 | (-8) | 928 | (-20) | 400 | (31) | 278 | (32) | 76 | (-11) | 31 | (153) | 672 | (23) | 483 | (0) |
| Total | 4,278 | (15) | 3,367 | (19) | 1,561 | (15) | 1,039 | (21) | 218 | (22) | 138 | (30) | 6,057 | (15) | 2,645 | (22) |
| Key figures | ||||||||||||||||
| Gross margin – % | 61 | 14 | 20.0 | 19.8 | 42.7 | 11.0 | 64 | 12 | 6.9 | 6.9 | 14.4 | 11.0 | 60 | 13 | 3.4 | 3.4 |
| EBITDA margin – % | 11.6 | 11.5 | 11.6 | 8.1 | – | – | – | – | – | – | – | – | – | – | – | – |
| Earnings per share (EPS) – DKK | 11.6 | 8.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Earnings per share diluted (DEPS) – DKK | ||||||||||||||||
| Cash flow per share (CFPS)– DKK | 10.3 | |||||||||||||||
| Share price/Net asset value |
| Europe | North America | International markets | Total revenue | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | % | 2020 | % | 2021 | % | 2020 | % | 2021 | % | 2020 | % | 2021 | % | 2020 | % | |
| SCIT/SLIT-drops | 2,809 | (10) | 1,099 | (9) | 795 | (7) | 366 | (-7) | 111 | (6) | 31 | (153) | 3,715 | (6) | 1,774 | (29) |
| SLIT-tablets | 1,273 | (-4) | 1,340 | (31) | 366 | (-7) | 400 | (31) | 31 | (15) | 76 | (11) | 1,670 | (17) | 388 | (5) |
| Other products and services | 196 | (-8) | 928 | (-20) | 400 | (31) | 278 | (32) | 76 | (11) | 31 | (153) | 672 | (23) | 483 | (0) |
| Total | 4,278 | (15) | 3,367 | (19) | 1,561 | (15) | 1,039 | (21) | 218 | (22) | 138 | (30) | 6,057 | (15) | 2,645 | (22) |
| Key figures | ||||||||||||||||
| Gross margin – % | 61 | 14 | 20.0 | 19.8 | 42.7 | 11.0 | 64 | 12 | 6.9 | 6.9 | 14.4 | 11.0 | 60 | 13 | 3.4 | 3.4 |
| EBITDA margin – % | 11.6 | 11.5 | 11.6 | 8.1 | – | – | – | – | – | – | – | – | – | – | – | – |
| Earnings per share (EPS) – DKK | 11.6 | 8.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Earnings per share diluted (DEPS) – DKK | ||||||||||||||||
| Cash flow per share (CFPS)– DKK | 10.3 | |||||||||||||||
| Share price/Net asset value |
| Europe | North America | International markets | Total revenue | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | % | 2020 | % | 2021 | % | 2020 | % | 2021 | % | 2020 | % | 2021 | % | 2020 | % | |
| SCIT/SLIT-drops | 2,809 | (10) | 1,099 | (9) | 795 | (7) | 366 | (-7) | 111 | (6) | 31 | (153) | 3,715 | (6) | 1,774 | (29) |
| SLIT-tablets | 1,273 | (-4) | 1,340 | (31) | 366 | (-7) | 400 | (31) | 31 | (15) | 76 | (11) | 1,670 | (17) | 388 | (5) |
| Other products and services | 196 | (-8) | 928 | (-20) | 400 | (31) | 278 | (32) | 76 | (11) | 31 | (153) | 672 | (23) | 483 | (0) |
| Total | 4,278 | (15) | 3,367 | (19) | 1,561 | (15) | 1,039 | (21) | 218 | (22) | 138 | (30) | 6,057 | (15) | 2,645 | (22) |
| Key figures | ||||||||||||||||
| Gross margin – % | 61 | 14 | 20.0 | 19.8 | 42.7 | 11.0 | 64 | 12 | 6.9 | 6.9 | 14.4 | 11.0 | 60 | 13 | 3.4 | 3.4 |
| EBITDA margin – % | 11.6 | 11.5 | 11.6 | 8.1 | – | – | – | – | – | – | – | – | – | – | – | – |
| Earnings per share (EPS) – DKK | 11.6 | 8.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Earnings per share diluted (DEPS) – DKK | ||||||||||||||||
| Cash flow per share (CFPS)– DKK | 10.3 | |||||||||||||||
| Share price/Net asset value |
Definitions: see page 90.
ALK-Abelló A/S
Bøge Allé 6-8
DK-2970 Hørsholm, Denmark
CVR no. 63 71 79 16
Tel. +45 45 74 75 76
www.alk.net
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.